Introduction {#s1}
============

Cancer progression is often accompanied by profound changes in cellular identity. Cellular identity, or differentiation state, influences not only intrinsic malignant potential, but also response to therapy, even in tumors harboring the same targetable mutations ([@bib4]). Although tissue of origin is a major determinant of cancer cell identity, cancer cells can also undergo lineage switching in the course of their natural history and in response to the selective pressure of targeted therapy. In lung adenocarcinoma, absence of the pulmonary lineage specifier NKX2-1/TTF1 correlates with non-pulmonary cellular identities and poor prognosis compared with NKX2-1-positive tumors ([@bib2]; [@bib3]). Moreover, lung adenocarcinomas can undergo lineage switching during the evolution of drug resistance that reduces their dependence on the oncogenic signaling pathway being targeted ([@bib40]). Taken together, these observations indicate that there is a need to understand the critical regulators of cancer cell identity.

In previous work, we and others have shown that loss of NKX2-1 is sufficient to cause lineage switching in a mouse model of KRAS^G12D^-driven lung adenocarcinoma ([@bib31]; [@bib46]; [@bib50]). *Nkx2-1* deletion in established tumors causes cancer cells to shed their pulmonary identity and adopt a gastric-like differentiation state characterized by extensive mucin production and expression of multiple gastrointestinal markers, including HNF4α and Gastrokine 1. These tumors morphologically resemble a subtype of human lung cancer called invasive mucinous adenocarcinoma (IMA), which also expresses gastrointestinal markers and is predominantly driven by *KRAS* mutations ([@bib14]). Approximately 10--15% of human lung adenocarcinomas express HNF4α with no detectable NKX2-1 (9), including both IMAs and more moderately differentiated tumors. In many of these tumors, the *NKX2-1* gene appears to be silenced by genetic and/or epigenetic mechanisms ([@bib17]; [@bib32]). Aside from NKX2-1 itself, the Polycomb Repressive Complex 2 (PRC2) appears to play a role in suppressing mucinous differentiation in KRAS-driven, p53-deficient lung adenocarcinoma ([@bib42]). However, the precise mechanisms by which a gastric gene expression program is activated in NKX2-1-deficient tumors remain to be fully elucidated.

Many of the gastrointestinal transcripts expressed in IMA are known targets of the forkhead box transcription factors FoxA1 and FoxA2 (FoxA1/2). These transcription factors govern the development of a variety of tissues and are expressed in both the adult lung and GI tract (reviewed in [@bib13]). FoxA1/2 are also expressed in both murine and human IMA ([Figure 1A](#fig1){ref-type="fig"} and [Figure 1---figure supplement 1A--B](#fig1s1){ref-type="fig"}). We previously found that *Nkx2-1* deletion in autochthonous lung tumors caused FoxA1/2 to re-localize from the regulatory elements of pulmonary-specific genes (such as *Sftpa1*) to those of genes (such as *Hnf4a*) that are expressed in both the GI tract and IMA ([@bib46]). Given that NKX2-1 physically interacts with FoxA1/2 ([@bib46]; [@bib34]), we hypothesized that NKX2-1 promotes FoxA1/2 interaction with regulatory elements of the pulmonary differentiation program at the expense of those governing gastric identity. However, these data did not demonstrate a functional role for FoxA1/2 in the activation of the gastric program in these tumors. To address this question directly, we used conditional alleles of *Foxa1* ([@bib10]) and *Foxa2* ([@bib48]) to abrogate their function in an autochthonous mouse model of NKX2-1-negative lung adenocarcinoma. We found that FoxA1/2 are critical and redundant regulators of both the gastric differentiation program and growth of NKX2-1-negative tumors. Moreover, we found that the cellular identity adopted by tumors was highly dependent on the context in which FoxA1/2 activity is lost, suggesting that a cell's baseline epigenetic state can influence the identity it adopts in response to changes in lineage specifier expression.

![FoxA1 and FoxA2 are required for mucinous lung adenocarcinoma formation.\
Photomicrographs of lung neoplasia arising 11 weeks after initiation with PGK-Cre lentivirus. All mice are *Kras^LSL-G12D/+^; Nkx2-1^F/F^* and harbor conditional alleles of *Foxa1* and/or *Foxa2* as indicated. (**A**) Hematoxylin and eosin (H and E) and immunohistochemistry (IHC) for NKX2-1, FoxA1 and FoxA2. Arrows indicate neoplasia lacking expression of all three proteins. Scale bar: 100 microns. (**B**) Alcian blue stain for mucin production. Scale bar: 50 microns. (**C**) IHC for markers of gastrointestinal differentiation HNF4α, PK-L and PDX1. Scale bar: 100 microns.](elife-38579-fig1){#fig1}

Results {#s2}
=======

FoxA1 and FoxA2 are required for development of invasive mucinous adenocarcinoma of the lung {#s2-1}
--------------------------------------------------------------------------------------------

To test the hypothesis that FoxA1/2 are required for lung adenocarcinoma cells to undergo a pulmonary to gastric lineage switch upon loss of NKX2-1 expression, we incorporated conditional alleles of *Foxa1* and *Foxa2* into a mouse model of NKX2-1-deficient lung adenocarcinoma ([@bib46]). In this model, intratracheal delivery of virus expressing Cre recombinase simultaneously activates a conditional allele of oncogenic *Kras* (*Kras^LSL-G12D/+^)* and silences conditional alleles of *Nkx2-1 (Nkx2-1^F/F^*) alone or in addition to *Foxa1* (*Foxa1^F/F^*) and/or *Foxa2* (*Foxa2^F/F^*). Initial evaluation by morphology (H and E) and immunohistochemistry (IHC) showed that tumors lacking either FoxA1 or FoxA2 were indistinguishable from control tumors ([Figure 1A](#fig1){ref-type="fig"}). In sharp contrast, concomitant deletion of *Foxa1* and *Foxa2* led to the emergence of small neoplastic lesions ([Figure 1A](#fig1){ref-type="fig"}, right column) in the alveoli that were completely devoid of the glandular architecture and mucin production that characterizes NKX2-1-deficient tumors. Absence of mucin production was apparent by H and E staining and further demonstrated by Alcian Blue staining ([Figure 1B](#fig1){ref-type="fig"}) and IHC for Muc5AC ([Figure 1---figure supplement 1C](#fig1s1){ref-type="fig"}).

Given the dramatic change in the morphology of lung neoplasia lacking NKX2-1, FoxA1 and FoxA2, we used IHC to assess the differentiation state of these lesions. Cytokeratin 8 (CK8) was expressed in lesions arising in mice of all genotypes ([Figure 1---figure supplement 1C](#fig1s1){ref-type="fig"}), showing that cells lacking all three transcription factors retained an epithelial identity and did not undergo a complete epithelial to mesenchymal transition. HNF4α and PDX1 are transcription factors that regulate gastrointestinal differentiation and are expressed in human invasive mucinous adenocarcinoma and mouse models of this disease ([@bib46]; [@bib45]). Both transcription factors, as well as the HNF4α target PK-L, were undetectable in FoxA1/2-deficient neoplasia ([Figure 1C](#fig1){ref-type="fig"}). Additional markers of gastrointestinal differentiation, including Gastrokine 1, Cathepsin E and Galectin 4, were also not expressed in these lesions ([Figure 1---figure supplement 1C](#fig1s1){ref-type="fig"}). All these markers were retained in lesions lacking either FoxA1 or FoxA2 alone ([Figure 1C](#fig1){ref-type="fig"} and [Figure 1---figure supplement 1C](#fig1s1){ref-type="fig"}). Taken together, these data show that FoxA1 and FoxA2 are required for mucin production and key elements of the gastrointestinal differentiation program in NKX2-1-negative lung tumors in a functionally redundant manner.

FoxA1 and FoxA2 are required at initiation for growth and proliferation of NKX2-1-negative lung adenocarcinoma {#s2-2}
--------------------------------------------------------------------------------------------------------------

Most lesions in *Kras^LSL-G12D/+^; Nkx2-1^F/F^; Foxa1^F/F^; Foxa2^F/F^* mice exhibited complete loss of FoxA1/2 expression when analyzed at 11 weeks post-infection. However, these mice also harbored a variable but substantial quantity of tumors ('incomplete recombinants') that retained FoxA1 or FoxA2 as well as targets such as HNF4α ([Figure 2---figure supplement 1A--B](#fig2s1){ref-type="fig"}). Since incomplete recombinants were often larger than the lesions lacking NKX2-1, FoxA1 and FoxA2 (i.e. 'complete recombinants') ([Figure 2---figure supplement 1B](#fig2s1){ref-type="fig"}), we speculated that they might have gradually outgrown the complete recombinants over time. Consistent with this possibility, we found that 5 weeks after tumor initiation, incomplete recombinants comprised a much smaller proportion of overall tumor burden than at 11 weeks ([Figure 2---figure supplement 1A--B](#fig2s1){ref-type="fig"}).

Based on these data, we chose the 5-week timepoint to quantitate tumor burden and proliferation rates among the different genotypes. We found that concomitant deletion of both *Foxa1* and *Foxa2* led to an approximately 10-fold reduction in tumor burden when measured at 5 weeks post-initiation ([Figure 2A](#fig2){ref-type="fig"}). This was accompanied by reduced lesion size and, to a lesser extent, fewer lesions/mm^2^ ([Figure 2---figure supplement 1C--D](#fig2s1){ref-type="fig"}). In contrast, deletion of either *Foxa1* or *Foxa2* alone had little to no effect on tumor burden.

![FoxA1 and FoxA2 are required for initiation and proliferation of NKX2-1-deficient lung adenocarcinoma.\
(**A**) Quantitation of tumor burden 5 weeks after initiation with PGK-Cre lentivirus in *Kras^LSL-G12D/+^; Nkx2-1^F/F^* mice of indicated genotype: control (n = 15), *Foxa1^F/F^* (n = 13), *Foxa2^F/F^* (n = 9) and *Foxa1^F/F^; Foxa2^F/F^* (n = 12). \*\*p \< 0.0002 vs. each group, Mann-Whitney. \*p=0.0425 vs. control. Graphs represent mean ±S.D. (**B**) Quantitation of BrdU incorporation in lung neoplasia 5 weeks after initiation with PGK-Cre lentivirus in *Kras^LSL-G12D/+^; Nkx2-1^F/F^* mice of indicated genotype: control (n = 7), *Foxa1^F/F^* (n = 4), *Foxa2^F/F^* (n = 4) and *Foxa1^F/F^; Foxa2^F/F^* (n = 7). \*p \< 0.005 vs. each control, Mann-Whitney. Graphs represent mean ±S.D. (**C**) Representative IHC for BrdU in *Kras^LSL-G12D/+^; Nkx2-1^F/F^* mice of indicated genotype quantitated in [Figure 2B](#fig2){ref-type="fig"}. Scale bar: 100 microns. (**D**) Long-term survival after tumor initiation with PGK-Cre lentivirus in *Kras^LSL-G12D/+^; Nkx2-1^F/F^* mice of indicated genotype: control (n = 9), *Foxa1^F/F^* (n = 10), *Foxa2^F/F^* (n = 12) and *Foxa1^F/F^; Foxa2^F/F^* (n = 9). p \< 0.0001, *Kras^LSL-G12D/+^; Nkx2-1^F/F^; Foxa1^F/F^; Foxa2^F/F^* mice vs. each control, Log-rank test.](elife-38579-fig2){#fig2}

To determine why loss of FoxA1/2 activity caused such a severe inhibition of tumorigenesis, we analyzed proliferation and apoptosis in tumors of each genotype. BrdU incorporation was reduced by \~50% in FoxA1/2-deficient lesions in comparison with control lesions ([Figure 2B--C](#fig2){ref-type="fig"}). IHC for the proliferation markers MCM2 and KI67 also demonstrated that FoxA1/2-deficient lesions proliferate at a significantly lower rate than controls ([Figure 2---figure supplement 1E--G](#fig2s1){ref-type="fig"}). In contrast, the apoptotic rate of FoxA1/2-deficient lesions was no different than controls as measured by IHC for cleaved caspase-3 ([Figure 2---figure supplement 1H](#fig2s1){ref-type="fig"}).

In addition to these short-term measurements, we assessed the long-term impact of *Foxa1/2* deletion in a survival analysis ([Figure 2D](#fig2){ref-type="fig"}). Mice in the three control groups survived for a similar duration after tumor initiation (median survival 143--160 days). In contrast, deletion of both *Foxa1* and *Foxa2* led to a dramatic increase in survival (median survival 293 days). Histopathologic analysis showed that approximately 80% of the tumor burden in *Kras^LSL-G12D/+^; Nkx2-1^F/F^; Foxa1^F/F^; Foxa2^F/F^* mice consisted of mucinous HNF4α-positive adenocarcinomas ([Figure 2---figure supplement 1A](#fig2s1){ref-type="fig"}). This suggests that these mice ultimately succumbed to growth of incomplete recombinants and that the complete recombinants likely had little impact on overall survival. We also noted extensive extracellular mucin secretion in the tumors of *Kras^LSL-G12D/+^; Nkx2-1^F/F^; Foxa1^F/F^* mice ([Figure 2---figure supplement 1I](#fig2s1){ref-type="fig"}). This phenomenon was rarely observed in tumors from other control groups, which predominantly produced intracellular mucin, suggesting that FoxA1 and FoxA2 likely have some specific functions in the regulation of the differentiation state of NKX2-1-negative adenocarcinoma. Taken together, these data show that lack of FoxA1/2 activity at tumor initiation severely impairs the proliferation and long-term growth potential of NKX2-1-negative lung adenocarcinoma.

FoxA1 and FoxA2 are required for global activation of the gastric differentiation program in NKX2-1-negative lung adenocarcinoma {#s2-3}
--------------------------------------------------------------------------------------------------------------------------------

We next sought to analyze the changes in gene expression induced by deletion of *Foxa1* and *Foxa2* in NKX2-1-deficient tumors. Our mice harbor a Cre-dependent tdTomato reporter allele ([@bib30]) that enables tumor cell isolation by fluorescence-activated cell sorting (FACS). For sorting experiments, we initiated tumors with the Ad5-SPC-Cre adenovirus ([@bib49]), which restricts Cre activity to SPC-positive lung epithelial cells, obviating the need to exclude stromal cells from the sorted population. (SPC-Cre induces lesions identical to lentiviral-driven Cre (Figure 6 and data not shown)). However, we lacked a cell surface marker that would enable us to differentially isolate complete from incomplete recombinants in *Kras^LSL-G12D/+^; Nkx2-1^F/F^; Foxa1^F/F^; Foxa2^F/F^* mice during sorting.

Single-cell RNA-Seq can be used to deconvolute gene expression profiles of mixed cell populations from the murine lung bioinformatically and thereby assign an identity to each cell ([@bib52]). We therefore proceeded with single-cell RNA-Seq analysis on FACS-sorted lung tumor cells via the Fluidigm C1 Autoprep microfluidic system. We sorted tumor cells from one *Kras^LSL-G12D/+^* mouse, one *Kras^LSL-G12D/+^; Nkx2-1^F/F^* mouse, and two *Kras^LSL-G12D/+^; Nkx2-1^F/F^; Foxa1^F/F^; Foxa2^F/F^* mice. After Illumina sequencing and transcript quantitation, we used the SC3 clustering package ([@bib22]) for quality control, filtering and clustering. A total of 134 cells were considered to be of sufficient quality for further analysis ([Supplementary files 1](#supp1){ref-type="supplementary-material"}--[2](#supp2){ref-type="supplementary-material"}), which yielded three distinct clusters (tSNE plot, [Figure 3A](#fig3){ref-type="fig"}).

![Deletion *Nkx2-1*, *Foxa1* and *Foxa2* at initiation blocks gastric differentiation and induces expression of squamocolumnar junctional markers in lung neoplasia.\
(**A**) tSNE plot of single-cell mRNA-Seq data derived from murine lung tumor cells (n = 134). Cells were sorted based on tdTomato expression from mice of the following genotypes: *Kras^LSL-G12D/+^*(K), n = 1 mouse), *Kras^LSL-G12D/+^; Nkx2-1^F/F^* (KN), n = 1 mouse), *Kras^LSL-G12D/+^; Nkx2-1^F/F^; Foxa1^F/F^; Foxa2^F/F^* (KNF1F2, n = 2 mice). Color indicates cancer cell cluster. Shape indicates genotype of mouse from which cell was isolated. (**B**) tSNE plot of three cancer cell clusters (C1--C3) and a panel of normal murine tissue. 'Glandular' indicates glandular stomach. (**C**) IHC for indicated proteins in lung neoplasia 5 weeks after initiation with PGK-Cre lentivirus in *Kras^LSL-G12D/+^; Nkx2-1^F/F^; Foxa1^F/F^; Foxa2^F/F^* mice and NKX2-1-negative controls. SCJ: normal squamocolumnar junction (forestomach on left, glandular stomach on right). Scale bar: 100 microns.](elife-38579-fig3){#fig3}

Cluster 1 (C1, n = 62 cells) contained cells from mice of all three genotypes. Using the SC3 package, we identified marker genes for this cluster (defined as \'genes that are highly expressed in only one of the clusters and are able to distinguish one cluster from all the remaining ones'). These included canonical NKX2-1 target genes *Sftpa1* and *Sftpb* ([Supplementary file 3](#supp3){ref-type="supplementary-material"}). From these data, we infer that C1 represents tumor cells that are phenotypically NKX2-1-positive. In contrast, cluster 2 (C2, n = 31 cells) only contained cells from *Kras^LSL-G12D/+^; Nkx2-1^F/F^* and *Kras^LSL-G12D/+^; Nkx2-1^F/F^; Foxa1^F/F^; Foxa2^F/F^* mice. Numerous gastrointestinal transcripts were identified as marker genes for this cluster, including *Hnf4a*, *Gkn1*, *Lgals4* and *Ctse*. Thus, C2 appears to include incomplete recombinants from *Kras^LSL-G12D/+^; Nkx2-1^F/F^; Foxa1^F/F^; Foxa2^F/F^* mice that express sufficient levels of FoxA1 and/or FoxA2 to maintain a gastric differentiation state. In contrast, cluster 3 (C3, n = 41 cells) contained only cells from *Kras^LSL-G12D/+^; Nkx2-1^F/F^; Foxa1^F/F^; Foxa2^F/F^* mice and expressed marker genes not characteristic of either a pulmonary or gastric differentiation state, suggesting that C3 likely contains cells completely deficient for NKX2-1, FoxA1 and FoxA2 (i.e. complete recombinants).

Several different analyses further validated our classification of C1 and C2 as NKX2-1-positive and NKX2-1-negative cells, respectively. First, we identified differentially expressed genes between C1 and C2 using an independent software package (SCDE) and found that many pulmonary and gastric transcripts were differentially expressed between the two clusters ([Supplementary file 3](#supp3){ref-type="supplementary-material"}). We then performed RNA-Seq on sorted bulk tumor cells from *Kras^LSL-G12D/+^* and *Kras^LSL-G12D/+^; Nkx2-1^F/F^* mice (n = 3 each, [Supplementary file 4](#supp4){ref-type="supplementary-material"}) and found a strong correlation (Pearson correlation coefficient = 0.62) between the differentially expressed genes identified in single cell and bulk analyses ([Figure 3---figure supplement 1A](#fig3s1){ref-type="fig"}). We also compared our single-cell datasets with published data from other groups. We found that normal murine type two pneumocytes ([@bib52]), which are the presumed cell of origin for NKX2-1-positive tumor cells, clustered with presumptive NKX2-1-positive C1 cells ([Figure 3---figure supplement 1B](#fig3s1){ref-type="fig"}). We also used principal component analysis (PCA) to compare our single-cell data with a gene signature of human IMA ([@bib14]). In this analysis, the IMA signature caused C2 cells to cluster separately from the other cells ([Figure 3---figure supplement 1C](#fig3s1){ref-type="fig"}). This shows that C2 cells are more similar to IMA than C1 and C3, as would be expected if they represent the NKX2-1-negative tumor cell population.

NKX2-1; FoxA1/2-deficient tumor cells express markers of the squamocolumnar junctional epithelium of the GI tract {#s2-4}
-----------------------------------------------------------------------------------------------------------------

To characterize the identity of our tumor cells in a global manner, we compared our single-cell RNA-Seq data with total RNA-Seq data from a panel of mouse tissues ([Supplementary file 5](#supp5){ref-type="supplementary-material"}). The 50 genes in each tissue with the highest expression compared to the other tissues in the panel were identified. Expression data for this set of genes was extracted from the single cell and tissue datasets and evaluated using two approaches: tSNE ([Figure 3B](#fig3){ref-type="fig"}) and hierarchical clustering on principal components (HCPC, [Figure 3---figure supplement 1D](#fig3s1){ref-type="fig"}), which combines PCA, hierarchical clustering and k-means clustering. In both approaches, we found that C1 was most similar to normal lung, and that C2 was most similar to glandular stomach. C3 cells clustered near the upper GI tract, in particular the forestomach and esophagus. However, cosine similarity analysis ([Supplementary file 6](#supp6){ref-type="supplementary-material"}) showed that C3 cells are not as closely related to esophagus/forestomach as C1 and C2 are to lung and glandular stomach, respectively. This bioinformatic analysis is in consonance with microscopic evaluation of complete recombinants, which lack morphological features of a multi-layered, keratinizing squamous epithelium ([Figure 1](#fig1){ref-type="fig"}) that is found in the normal esophagus and forestomach. Moreover, the vast majority of complete recombinants cells do not express ΔNp63, a master regulator of squamous differentiation, or the squamous marker cytokeratin 5 (CK5) ([Figure 3---figure supplement 1E](#fig3s1){ref-type="fig"}). Thus, complete ablation of NKX2-1, FoxA1 and FoxA2 causes lung tumor cells to adopt an identity that is neither pulmonary nor gastric, but also is not fully squamous. Indeed, it appears that the exact differentiation state adopted by these cells is not well represented in the panel of tissues evaluated.

Recent studies have described a small but discrete transitional zone at the squamocolumnar junction (SCJ) of the gastrointestinal (GI) tract, just proximal to the glandular stomach, which is not included as a discrete entity in our tissue panel. This transitional zone consists of a bilayered epithelium expressing high levels of cytokeratin 7 (CK7) ([@bib19]; [@bib54]), including a ΔNp63/CK5-positive basal layer and a ΔNp63/CK5-negative luminal layer. Intriguingly, complete recombinants in *Kras^LSL-G12D/+^; Nkx2-1^F/F^; Foxa1^F/F^; Foxa2^F/F^* mice have uniformly high levels of CK7 protein that are comparable to the SCJ ([Figure 3C](#fig3){ref-type="fig"}).

Manual inspection of genes specifically expressed in C3 vs. both C1 and C2 (using both SC3 and SCDE) revealed that several of these genes are expressed at high levels at the SCJ of the GI tract and/or the cervix. These genes include *Chil4* ([@bib37]), *Gda* and *Mmp7* ([@bib15]), and *Vcam1* ([Figure 3C](#fig3){ref-type="fig"}). Other C3-specific genes are expressed at higher levels throughout the forestomach and esophagus than glandular stomach, including *Cav1*, *Cdh13*, *Hilpda*, *Fbln2* and *Rbp7* ([@bib53]). Using IHC, we found that protein levels of several these genes are much higher in complete recombinants than in NKX2-1-negative lesions ([Figure 3C](#fig3){ref-type="fig"} and [Figure 3---figure supplement 1E](#fig3s1){ref-type="fig"}).

These data led us to evaluate FoxA1/2 levels at the SCJ of the murine GI tract ([Figure 3---figure supplement 1F](#fig3s1){ref-type="fig"}). Both FoxA1 and FoxA2 are expressed in the glandular stomach. Interestingly, FoxA2 expression ends at the SCJ and is absent throughout the squamous forestomach and esophagus. In contrast, FoxA1 levels are very low but detectable at the SCJ then increase in the proximal forestomach and esophagus. Thus, overall FoxA1/2 levels appear to reach their nadir at the SCJ and distal forestomach of the normal murine GI tract. Taken together, our data show that FoxA1/2 are required for NKX2-1-deficient lung tumor cells to adopt a gastric identity. Moreover, concomitant loss of NKX2-1 and FoxA1/2 activity at tumor initiation leads to a distinct differentiation state characterized by expression of multiple markers of the transitional epithelium normally found at the SCJ of the GI tract.

FoxA1/2 are downregulated in the squamous component of murine and human adenosquamous carcinoma of the lung {#s2-5}
-----------------------------------------------------------------------------------------------------------

Although *Kras^LSL-G12D/+^; Nkx2-1^F/F^; Foxa1^F/F^* and *Kras^LSL-G12D/+^; Nkx2-1^F/F^; Foxa2^F/F^* mice exhibited minimal obvious phenotypes at early timepoints ([Figures 1](#fig1){ref-type="fig"}--[2](#fig2){ref-type="fig"}), we found that a subset of these mice developed macroscopic adenosquamous carcinomas (AdSCCs) at 20 weeks post-initiation ([Figure 4](#fig4){ref-type="fig"} and [Figure 4---figure supplement 1A](#fig4s1){ref-type="fig"}). In contrast, we did not find AdSCCs in any of the *Kras^LSL-G12D/+^; Nkx2-1^F/F^* mice aged to 20 weeks post-initiation. Human AdSCC is an uncommon but aggressive lung cancer subtype that contains a mix of clonally related adenocarcinoma and squamous cell components ([@bib43]; [@bib51]). In our mice, AdSCCs consisted of a mucinous adenocarcinoma component that was continuous with, and typically circumscribed, a well-differentiated, keratinizing squamous cell carcinoma component ([Figure 4A--C](#fig4){ref-type="fig"}). Both components were tdTomato-positive, indicating that these tumors had arisen through Cre-mediated recombination ([Figure 4B](#fig4){ref-type="fig"}). Although both components were NKX2-1-negative, markers of gastric differentiation were restricted to the adenocarcinoma component, and markers of squamous differentiation (including ΔNp63 and cytokeratins 5 and 14 (CK5 and CK14), but not SOX2) were selectively expressed in the SCC component ([Figure 4B](#fig4){ref-type="fig"} and [Figure 4---figure supplement 1C](#fig4s1){ref-type="fig"}).

![FoxA1 and FoxA2 are downregulated in the squamous component of murine and human adenosquamous lung carcinoma.\
(**A**) H and E of AdSCC arising in *Kras^LSL-G12D/+^; Nkx2-1^F/F^; Foxa2^F/F^* mouse. Scale bar: 1000 microns. (**B**) H and E and IHC of adenocarcinoma (left) and squamous (right) components of AdSCC arising in *Kras^LSL-G12D/+^; Nkx2-1^F/F^; Foxa2^F/F^* mouse. Scale bar: 100 microns. (**C**) Dual IHC for ΔNp63 (brown) and FoxA1/2 (purple) in AdSCC arising in *Kras^LSL-G12D/+^; Nkx2-1^F/F^; Foxa2^F/F^* mouse. Scale bar: 1000 microns. (**D**) Percent of human AdSCC cases (n = 12) exhibiting downregulation of FoxA1 and/or FoxA2 expression in the SCC component as assessed by IHC. (**E**) Representative IHC for FoxA1 and FoxA2 in a human AdSCC exhibiting downregulation of both proteins in the SCC component. Scale bar: 100 microns.](elife-38579-fig4){#fig4}

Given that genetic deletion of *Foxa1* and *Foxa2* at initiation completely suppressed mucinous gastric differentiation, we evaluated expression of both transcription factors in AdSCCs. In *Kras^LSL-G12D/+^; Nkx2-1^F/F^; Foxa2^F/F^* mice, we found that FoxA2 was absent in both components, whereas FoxA1 was expressed in the adenocarcinoma components but absent in the SCC ([Figure 4B](#fig4){ref-type="fig"}). AdSCC in the *Kras^LSL-G12D/+^; Nkx2-1^F/F^; Foxa1^F/F^* mouse exhibited the opposite pattern, that is, FoxA1 loss in both components and FoxA2 expression only in the adenocarcinoma component ([Figure 4---figure supplement 1B](#fig4s1){ref-type="fig"}). Thus, the SCC component is always associated with stochastic loss of FoxA1/2 expression. Given that *Kras^LSL-G12D/+^; Nkx2-1^F/F^; Foxa1^F/F^; Foxa2^F/F^* mice contain incomplete recombinants that retain either FoxA1 or FoxA2, we also observed AdSCCs in a subset of these mice at 20 weeks ([Figure 4---figure supplement 1A](#fig4s1){ref-type="fig"}). As expected, AdSCCs in *Kras^LSL-G12D/+^; Nkx2-1^F/F^; Foxa1^F/F^; Foxa2^F/F^* mice always expressed either FoxA1 or FoxA2 in the adenocarcinoma component and stochastic loss of the other paralogue in the squamous component.

These data suggest that when only one FoxA paralogue is expressed in mucinous lung adenocarcinoma, stochastic loss of the other FoxA paralogue can occur as the tumors progress. This stochastic loss of FoxA activity is associated with a profound change in differentiation state, with FoxA1/2-negative cells upregulating a keratinizing squamous differentiation program. This is in sharp contrast to the differentiation state of tumor cells in which FoxA1/2 loss was engineered at the time of tumor initiation ([Figure 3](#fig3){ref-type="fig"}), which led to an SCJ-like phenotype. These results raise the possibility that the genetic and/or epigenetic context in which FoxA1/2 activity is lost may have a significant influence on the cellular identity adopted by lung tumor cells.

We next analyzed FoxA1/2 expression by IHC in human AdSCC (n = 12) to determine whether these transcription factors are differentially expressed between adenocarcinoma and squamous components ([Figure 4D--E](#fig4){ref-type="fig"}). FoxA1 and FoxA2 were expressed in the adenocarcinoma component of all cases. In half of the cases, FoxA1 and FoxA2 were both downregulated in the squamous component (n = 5 cases with complete loss of expression and n = 1 case with detectable but diminished expression). In the other half, either FoxA1 (n = 5) or FoxA2 (n = 1) exhibited downregulation in the squamous component. Thus, half of the human AdSCC examined exhibit the same pattern of FoxA1/2 downregulation that we observe in our mouse model. Moreover, all cases exhibit at least partial reduction in expression of FoxA1 or FoxA2 in the squamous component. Taken together, these data suggest that reduced FoxA activity is commonly associated with adenosquamous transdifferentiation in human lung cancer.

Context-dependent induction of squamous cell carcinoma by loss of FoxA1/2 {#s2-6}
-------------------------------------------------------------------------

To test the hypothesis that loss of FoxA1/2 activity might promote squamous differentiation only in specific contexts, we generated *Kras^FSF-G12D/+^; Rosa^FSF-CreERT2^; Nkx2-1^F/F^; Foxa1^F/F^; Foxa2^F/F^* mice as well as controls wild type for either *Foxa1* or both *Foxa1* and *Foxa2*. In these mice, delivery of the FlpO recombinase (via Ad5CMV-FlpO adenovirus) to the lung epithelium activates transcription of the *Kras^G12D^* oncogene from its endogenous locus ([@bib58]) and transcription of Cre^ERT2^ from the *Rosa26* locus ([@bib41]). Tamoxifen is then used to activate the Cre^ERT2^ protein and drive recombination of lineage specifiers in KRAS^G12D^-expressing lung neoplasia. To determine whether loss of NKX2-1, FoxA1 and FoxA2 in established neoplasia was sufficient to induce full squamous differentiation, we administered tamoxifen 1 week after tumor initiation with Ad5CMV-FlpO, then analyzed tumors 4 weeks later (outline in [Figure 5A](#fig5){ref-type="fig"}).

![Uncoupling KRAS^G12D^ activation from lineage specifier deletion promotes squamous cell carcinoma formation in the lung.\
(**A**) Schematic of experimental design. (**B**) H and E and IHC for indicated proteins in tumors from mice harboring the conditional alleles *Kras^FSF-G12D/+^; Rosa^FSF-CreERT2^; Nkx2-1^F/F^* (controls) alone and in combination with either *Foxa2^F/F^* or *Foxa1^F/F^; Foxa2^F/F^*. 'K' indicates acellular keratin. All mice were given tamoxifen 1 week after tumor initiation. Tamoxifen administration consisted of six intraperitoneal doses over nine days, followed by tamoxifen-containing chow until the end of the experiment. Scale bar: 50 microns.](elife-38579-fig5){#fig5}

Histopathologic analysis of controls showed that the lungs contained mucinous adenocarcinoma that expressed HNF4α and the expected pattern of FoxA1/2 ([Figure 5B](#fig5){ref-type="fig"} and [Figure 5---figure supplement 1A](#fig5s1){ref-type="fig"}). Almost all lesions in *Nkx2-1^F/F^* and *Nkx2-1^F/F^; Foxa2^F/F^* mice were ΔNp63-negative ([Figure 5B](#fig5){ref-type="fig"} and [Figure 5---figure supplement 1C](#fig5s1){ref-type="fig"}). Indeed, only one mouse in each control group exhibited a single lesion with ΔNp63-positive cells. In contrast, all *Kras^FSF-G12D/+^; Rosa^FSF-CreERT2^; Nkx2-1^F/F^; Foxa1^F/F^; Foxa2^F/F^* mice harbored numerous non-mucinous lesions lacking FoxA1/2 and HNF4α. Most of these lesions were morphologically similar to the SCJ-like lesions generated with Cre-mediated recombination at tumor initiation ([Figure 1](#fig1){ref-type="fig"}).

Strikingly, four out of eight *Kras^FSF-G12D/+^; Rosa^FSF-CreERT2^; Nkx2-1^F/F^; Foxa1^F/F^; Foxa2^F/F^* mice harbored well-differentiated squamous cell carcinomas (SCCs) characterized by a stratified squamous epithelium with extensive keratinization ([Figure 5B](#fig5){ref-type="fig"} and [Figure 5---figure supplement 1B](#fig5s1){ref-type="fig"}). In contrast to the AdSCCs that arise stochastically from mucinous adenocarcinomas ([Figure 4](#fig4){ref-type="fig"}), these SCCs appeared to be discrete lesions and were not surrounded by HNF4α-positive mucinous adenocarcinoma ([Figure 5B](#fig5){ref-type="fig"}). As expected, all SCCs in this model expressed ΔNp63 ([Figure 5B](#fig5){ref-type="fig"}). Interestingly, we even detected ΔNp63 in a significant minority of non-keratinizing lesions in these mice ([Figure 5B](#fig5){ref-type="fig"}), which contrasts with the lack of ΔNp63 expression in the complete recombinants of *Kras^LSL-G12D/+^; Nkx2-1^F/F^; Foxa1^F/F^; Foxa2^F/F^* mice ([Figure 3---figure supplement 1E](#fig3s1){ref-type="fig"}).

Most of the microscopic analysis of *Kras^LSL-G12D/+^; Nkx2-1^F/F^; Foxa1^F/F^; Foxa2^F/F^* mice ([Figures 1](#fig1){ref-type="fig"}--[4](#fig4){ref-type="fig"}) was performed on lesions generated with lentivirus expressing Cre under the control of the *Pgk* promoter. To control for the possibility that the use of adenovirus and/or the CMV promoter might have played a role in the phenotypes observed with sequential recombination, we infected *Kras^LSL-G12D/+^; Nkx2-1^F/F^; Foxa1^F/F^; Foxa2^F/F^* mice (n = 6) with Ad5CMV-Cre and harvested tumors 5 weeks after infection. Importantly, none of the mice harbored SCCs, despite the presence of multiple complete recombinants ([Figure 5---figure supplement 1C](#fig5s1){ref-type="fig"}). Interestingly, ΔNp63 expression was slightly higher in these lesions than in lesions from mice of the same genotype infected with Pgk-Cre lentivirus (data not shown).

Taken together, these data identify a specific context in which loss of FoxA1/2 activity is sufficient to induce full squamous differentiation in the lung. Since FoxA1/2 loss was induced only 1 week after KRAS^G12D^ expression in this experiment, it seems likely that enhanced competence for squamous differentiation is a direct result of KRAS^G12D^ expression rather than stochastic genetic alterations accruing over time. Moreover, the fact that only a subset of neoplastic lesions are keratinizing SCC raises the possibility that a specific subpopulation of lung epithelial cells may exhibit enhanced competence for squamous differentiation in this system.

Squamous cell carcinoma arises from SPC-positive lung epithelial cells {#s2-7}
----------------------------------------------------------------------

To define more precisely the cell type from which SCCs arise in the sequential recombination model, we generated an adenovirus in which expression of the FlpO recombinase is driven by the murine SPC promoter. This promoter has been extensively validated to drive Cre expression primarily in type 2 pneumocytes of the alveoli ([@bib49]). To validate this promoter in our sequential recombination system, we generated *Kras^FSF-G12D/+^; Rosa^FSF-CreERT2^* harboring a *CAG-LSL-HA-UPRT* transgene ([@bib11]), in which the HA-tagged UPRT enzyme is only expressed after Cre-based recombination of the STOP cassette. These mice were infected with Ad5-SPC-FlpO or Ad5-CMV-FlpO, treated with tamoxifen 1-week post-infection, and subjected to histopathologic analysis 3 weeks post-infection. Whereas recombination was readily detectable in the bronchioles and alveoli of Ad5-CMV-FlpO infected mice, recombination was restricted to the alveoli of Ad5-SPC-FlpO infected mice ([Figure 6---figure supplement 1A](#fig6s1){ref-type="fig"}).

Next, we infected a cohort of *Kras^FSF-G12D/+^; Rosa^FSF-CreERT2^; Nkx2-1^F/F^; Foxa1^F/F^; Foxa2^F/F^* mice, along with *Kras^FSF-G12D/+^; Rosa^FSF-CreERT2^; Nkx2-1^F/F^* controls with Ad5-SPC-FlpO. As an additional control, we infected a group of *Kras^LSL-G12D/+^; Rosa^LSL-tdTomato^; Nkx2-1^F/F^; Foxa1^F/F^; Foxa2^F/F^* mice with Ad5-SPC-Cre. All mice were treated with tamoxifen 1 week after infection and analyzed 5 weeks after infection. As expected, the lungs of *Kras^FSF-G12D/+^; Rosa^FSF-CreERT2^; Nkx2-1^F/F^* controls harbored numerous mucinous lesions in the alveoli that expressed FoxA1/2 and lacked squamous markers such as ΔNp63 and CK5 ([Figure 6](#fig6){ref-type="fig"}, left panel). *Kras^FSF-G12D/+^; Rosa^FSF-CreERT2^; Nkx2-1^F/F^; Foxa1^F/F^; Foxa2^F/F^* mice harbored FoxA1/2-negative lesions of two distinct morphologies ([Figure 6](#fig6){ref-type="fig"}, central panels). All mice harbored SCJ-like lesions that were predominantly CK7-positive/CK5-negative and expressed ΔNp63 in a minority of cells. Moreover, 63% of these mice (n = 5 out of 8) harbored well-differentiated, keratinizing SCCs that were CK7-negative/CK5-positive and expressed ΔNp63 ([Figure 6](#fig6){ref-type="fig"}, central panels and [Figure 6---figure supplement 1B](#fig6s1){ref-type="fig"}). Overall, these phenotypes were very similar to those observed when tumors were initiated with Ad5-CMV-FlpO in these mice ([Figure 5](#fig5){ref-type="fig"}). Importantly, we did not identify SCC in any of the *Kras^LSL-G12D/+^; Rosa^LSL^-^tdTomato^; Nkx2-1^F/F^; Foxa1^F/F^; Foxa2^F/F^* mice infected with Ad5-SPC-Cre. These mice harbored CK7-positive/CK5-negative SCJ-like lesions that were essentially identical to lesions initiated by lentivirus in previous experiments ([Figures 1](#fig1){ref-type="fig"}--[3](#fig3){ref-type="fig"}).

![SPC-positive cells give rise to squamous cell carcinoma when KRAS^G12D^ activation is uncoupled from lineage specifier deletion.\
H and E and IHC for indicated proteins in neoplasia 5 weeks post initiation. In mice harboring the conditional alleles *Kras^FSF-G12D/+^; Rosa^FSF-CreERT2^; Nkx2-1^F/F^* (controls) alone and in combination with *Foxa1^F/F^; Foxa2^F/F^*, lung tumors were in initiated with Ad5-SPC-FlpO adenovirus. In mice harboring the conditional alleles *Kras^LSL-G12D/+^; Rosa^LSL-tdTomato^; Nkx2-1^F/F^; Foxa1^F/F^; Foxa2^F/F^*, tumors were initiated with Ad5-SPC-Cre (right column). All mice were given tamoxifen 1 week after tumor initiation. Tamoxifen administration consisted of four intraperitoneal doses over 5 days, followed by tamoxifen-containing chow until the end of the experiment. Scale bar: 100 microns.](elife-38579-fig6){#fig6}

Taken together, these data show that loss of NKX2-1, FoxA1, and FoxA2 in SPC-positive alveolar cells has distinct outcomes depending on the state of oncogenic signaling in these cells. When these lineage specifiers are lost in normal SPC-positive cells (concomitant with KRAS^G12D^ activation), the resulting neoplasia equilibrates to a uniform SCJ-like state marked by a CK7-positive/CK5-negative immunophenotype. In contrast, SPC-positive cells that have already been subjected to oncogenic signaling from KRAS^G12D^ for \~1 week have the potential to undergo full squamous transdifferentiation (CK7-negative/CK5-positive) and become well-differentiated keratinizing SCCs.

Discussion {#s3}
==========

Lung adenocarcinomas can adopt a variety of differentiation states, and changes in cellular identity can have both prognostic and therapeutic implications for patients with this disease. We have previously shown that engineered loss of the pulmonary lineage specifier NKX2-1 causes lung adenocarcinoma cells to shed their pulmonary identity and adopt a gastric differentiation state that is also observed in human IMA ([@bib46]). Here, we show that FoxA1 and FoxA2 are required for lung adenocarcinomas to adopt a mucinous, gastric differentiation state in the absence of NKX2-1. Although FoxA1/2 can regulate lung adenocarcinoma biology individually in some contexts ([@bib28]), their functional redundancy in IMA is consistent with their frequently redundant role in endodermal tissue specification (reviewed in [@bib13]). The precise mechanisms by which FoxA1/2 specifically activate a gastric program in NKX2-1 negative lung cancer, as opposed to other potential endodermal differentiation states (e.g. hepatic, pancreatic, lower GI tract etc.), remain to be determined. However, it appears likely that FoxA1/2 regulate gastrointestinal differentiation programs in other types of cancer. For example, pancreatic ductal adenocarcinoma (PDAC) and its precursors often express many of the same foregut markers as NKX2-1-negative lung adenocarcinoma ([@bib50]; [@bib1]; [@bib38]). FoxA1/2 levels are much higher in the subset of PDAC expressing a foregut differentiation program than in those tumors with a more mesenchymal/squamous differentiation state ([@bib1]). In addition, aberrant activation of a gastrointestinal differentiation program in prostate cancer, which can mediate castration resistance, is driven by HNF4γ in cooperation with FoxA1 ([@bib44]).

Interestingly, the precise consequences of FoxA1/2 loss in lung cancer are highly dependent on the specific context in which it occurs (model, [Figure 7](#fig7){ref-type="fig"}). When *Nkx2-1*, *Foxa1* and *Foxa2* are deleted at tumor initiation, the resulting lung lesions lacked evidence of either pulmonary or gastric differentiation ([Figure 3](#fig3){ref-type="fig"}). Instead, complete recombinants expressed several genes enriched at the SCJ of the GI tract, which contains a small but distinct non-keratinized transitional columnar epithelium marked by high levels of CK7 ([@bib19]). The transitional epithelium consists of a ΔNp63-positive basal progenitor layer, which can give rise to Barrett's metaplasia, and a differentiated ΔNp63-negative luminal layer. Thus, in the absence of FoxA1/2 activity, *Nkx2-1* deletion causes normal lung epithelial cells to adopt a cell fate resembling the transitional epithelium that localizes immediately proximal to the glandular stomach. Given the lack of ΔNp63 expression in complete recombinants, we speculate that these tumor cells more closely resemble the luminal cells of the transitional epithelium, which may account in part for their limited proliferative capacity.

![Model of context-specific regulation of lung cancer identity by NKX2-1, FoxA1 and FoxA2.\
SCJ: squamocolumnar junction of GI tract.](elife-38579-fig7){#fig7}

In contrast, both stochastic ([Figure 4](#fig4){ref-type="fig"}) and engineered ([Figures 5](#fig5){ref-type="fig"}--[6](#fig6){ref-type="fig"}) loss of FoxA1/2 in established KRAS^G12D^-driven lesions initiated in SPC-positive cells was accompanied by activation of a robust squamous differentiation program, as evidenced by a stratified multi-layered epithelium with extensive keratinization and expression of ΔNp63 and CK5. These data suggest that signaling from KRAS^G12D^ enhances the capacity of SPC-positive cells to activate a squamous differentiation program in the absence of NKX2-1 and FoxA1/2. Additional studies will be needed to determine the mechanism(s) that account for this enhanced propensity for squamous differentiation. ΔNp63 is an activator of squamous differentiation and is generally thought to function as an oncogene in SCC ([@bib55]), so the increased levels of ΔNp63 when *Nkx2-1;Foxa1/2* deletion occurs in established lesions ([Figures 5](#fig5){ref-type="fig"}--[6](#fig6){ref-type="fig"}) vs. at tumor initiation ([Figure 3](#fig3){ref-type="fig"}) are likely to be one major factor that dictates whether cells adopt an SCJ-like vs. SCC fate. We speculate that signaling from KRAS^G12D^ either alters the epigenetic state of elements regulating ΔNp63 directly, or influences the activity of its numerous upstream regulators ([@bib57]). It is also unclear why SPC-positive cells adopt two distinct fates in our sequential mutagenesis experiments (SCJ-like vs SCC, [Figure 6](#fig6){ref-type="fig"}). Intrinsic heterogeneity of the SPC-positive population (prior to KRAS^G12D^ expression) could account for this observation ([@bib21]; [@bib35]; [@bib59]). Alternatively, heterogeneous response to KRAS^G12D^ signaling could also play a role. Proliferation rate can influence changes in cell identity ([@bib47]), and it is possible that only a subset of SPC-positive cells are actively cycling one week after KRAS^G12D^ expression. Regardless, the fact that SPC-positive cells readily give rise to SCC contrasts with other investigations of cell type specificity in mouse models of SCC. In *Kras^G12D^; Lkb1* conditional mice CC10-positive lung epithelial cells are the predominant cell of origin for adenosquamous carcinomas, whereas SPC-positive cells mainly give rise to adenocarcinomas ([@bib36]; [@bib60]). In other murine models driven by SOX2 expression and either deletion of *Pten* and *Cdkn2ab* ([@bib9]) or *Nkx2-1* (7), both cell types can give rise to SCCs, although CC10-positive cells appeared to do so more efficiently.

Context also appears to be critical for the effect of FoxA1/2 loss on tumor growth. We have previously shown that *Nkx2-1* deletion augments KRAS^G12D^-driven tumorigenesis ([@bib46]). Concomitant *Foxa1/2* deletion at initiation reverses this phenotype ([Figure 2](#fig2){ref-type="fig"}), showing that when FoxA1/2 are absent at tumor initiation, NKX2-1-negative lesions equilibrate to a low proliferation state that never progresses to macroscopic disease. However, the stochastic emergence of macroscopic FoxA1/2-negative AdSCCs ([Figure 4](#fig4){ref-type="fig"}) argues that there is a selective advantage to loss of FoxA1/2 in some established lung neoplasia. This is further reinforced by the observation that a subset of human AdSCCs downregulate FoxA1/2 in their squamous component ([Figure 4](#fig4){ref-type="fig"}). An apparently dichotomous and context-specific contribution of FoxA1/2 to malignant potential has been observed in tumors from other tissues (reviewed in [@bib13]). For example, one study of human lung SCC reported that 43% of cases lacked FoxA1 expression by IHC, and that FoxA1 positivity was significantly correlated with unfavorable survival ([@bib6]). In PDAC, FoxA1 can promote metastasis ([@bib39]), despite the fact low levels of FoxA1/2 (as well as other lineage specifiers associated with endodermal differentiation) are found in the subtype of pancreatic ductal adenocarcinoma that confers the worst prognosis ([@bib1]). A comprehensive evaluation of FoxA1/2 loss at distinct stages of tumorigenesis will be needed to delineate fully its context-specific role in lung tumor growth.

In summary, this work expands our understanding of the lineage specifiers that coordinately regulate the growth and identity of lung adenocarcinoma. We show that FoxA1 and FoxA2 regulate the growth and gastric identity of NKX2-1-negative lung adenocarcinoma. In the absence of FoxA1/2 activity, NKX2-1-negative tumor cells adopt a more proximal cell fate with features of either the transitional epithelium of the SCJ or the squamous epithelium of the forestomach/esophagus, depending on the context of FoxA1/2 loss. Squamous transdifferentiation has been linked to drug resistance in human lung adenocarcinomas ([@bib16]), and it will be interesting to determine whether FoxA1/2 downregulation plays a role in this process. More broadly, our results show that the effects of lineage specifier inactivation in cancer can be highly context-dependent, and provide an experimental system for future work to elucidate the mechanistic basis for this specificity.

Materials and methods {#s4}
=====================

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\      Designation                            Source or\             Identifiers                                                                   Additional\
  (species)\                                                reference                                                                                            information
  or resource                                                                                                                                                    
  ------------------ -------------------------------------- ---------------------- ----------------------------------------------------------------------------- -----------------------
  Genetic reagent\   *Kras^LSL-G12D^*                       PMID:\                                                                                               Dr. Tyler Jacks\
  (*Mus musculus*)                                          11751630                                                                                             (Massachusetts\
                                                                                                                                                                 Institute of\
                                                                                                                                                                 Technology,\
                                                                                                                                                                 Cambridge,\
                                                                                                                                                                 Massachusetts)

  Genetic reagent\   *Kras^FSF-G12D^*                       PMID:\                 RRID:[MGI:5007794](https://scicrunch.org/resolver/MGI:5007794)                Dr. Tyler Jacks\
  (*M. musculus*)                                           21512139                                                                                             (Massachusetts\
                                                                                                                                                                 Institute of\
                                                                                                                                                                 Technology\
                                                                                                                                                                 , Cambridge,\
                                                                                                                                                                 Massachusetts)

  Genetic reagent\   *Rosa26^LSL-tdTomato^*                 PMID:\                 RRID:[MGI:4436847](https://scicrunch.org/resolver/MGI:4436847)                Jackson\
  (*M. musculus*)                                           20023653                                                                                             Laboratories\
                                                                                                                                                                 (Bar Harbor, Maine)

  Genetic reagent\   *Rosa26^FSF-CreERT2^*                  PMID:\                                                                                               Dr. Dieter Saur\
  (*M. musculus*)                                           25326799                                                                                             (Technische\
                                                                                                                                                                 Universität\
                                                                                                                                                                 München,\
                                                                                                                                                                 München, Germany)

  Genetic reagent\   *Nkx2-1^F/F^*                          PMID:\                 RRID:[MGI:3653706](https://scicrunch.org/resolver/MGI:3653706)                Dr. Shioko Kimura\
  (*M. musculus*)                                           16601074                                                                                             (National Cancer\
                                                                                                                                                                 Institute (NCI),\
                                                                                                                                                                 National Institutes\
                                                                                                                                                                 of Health, Bethesda,\
                                                                                                                                                                 Maryland)

  Genetic reagent\   *Foxa1^F/F^*                           PMID:\                 RRID:[MGI:3831163](https://scicrunch.org/resolver/MGI:3831163)                Dr. Klaus H.\
  (*M. musculus*)\                                          19141476                                                                                             Kaestner (University\
                                                                                                                                                                 of Pennsylvania\
                                                                                                                                                                 School of Medicine,\
                                                                                                                                                                 Philadelphia,\
                                                                                                                                                                 Pennsylvania,\
                                                                                                                                                                 USA)

  Genetic reagent\   *Foxa2^F/F^*                           PMID:\                 RRID:[MGI:2177357](https://scicrunch.org/resolver/MGI:2177357)                Dr. Klaus H.\
  (*M. musculus*)                                           10866673                                                                                             Kaestner (University\
                                                                                                                                                                 of Pennsylvania\
                                                                                                                                                                 School of Medicine,\
                                                                                                                                                                 Philadelphia,\
                                                                                                                                                                 Pennsylvania, USA)

  Genetic reagent\   *CAG-LSL-HA-UPRT*                      PMID: 23307870                                                                                       Jackson\
  (*M. musculus*)                                                                                                                                                Laboratories\
                                                                                                                                                                 (Bar Harbor,\
                                                                                                                                                                 Maine)\

  Cell line          293T                                   PMID:\                                                                                               
                                                            19561589                                                                                             

  Antibody           Rat monoclonal\                        Abcam                  Cat. \#:\                                                                     IHC (1:100)
                     anti-BrdU                                                     ab6326, RRID:\                                                                
                                                                                   [AB_305426](https://scicrunch.org/resolver/AB_305426)                         

  Antibody           Rabbit monoclonal\                     Abcam                  Cat. \#:\                                                                     IHC (1:250)
                     anti-Cadherin 13                                              ab167407                                                                      

  Antibody           Rabbit polyclonal\                     Lifespan\              Cat. \#:\                                                                     IHC (1:12000)
                     anti-Cathepsin E                       Biosciences            LS-B523, RRID:[AB_2087236](https://scicrunch.org/resolver/AB_2087236)         

  Antibody           Rabbit monoclonal\                     Abcam                  Cat. \#: ab192869                                                             IHC (1:4000)
                     anti-Caveolin 1                                                                                                                             

  Antibody           Rabbit monoclonal\                     Abcam                  Cat. \#: ab192029                                                             IHC (1:20000)
                     anti-CHIL3/4                                                                                                                                

  Antibody           Rabbit monoclonal\                     Cell Signaling\        Cat. \#: 9664                                                                 IHC (1:800)
                     anti-Cleaved-\                         Technology                                                                                           
                     caspase 3                                                                                                                                   

  Antibody           Rabbit monoclonal anti-Cytokeratin-5   Abcam                  Cat \#:\                                                                      IHC (1:400)
                                                                                   ab52635\                                                                      
                                                                                   (EP1691Y)                                                                     

  Antibody           Rabbit monoclonal\                     Abcam                  Cat \#:\                                                                      IHC (1:20,000)
                     anti-Cytokeratin-7                                            ab181598\                                                                     
                                                                                   (EP17078)                                                                     

  Antibody           Rat monoclonal\                        Developmental\         Cat. \#:\                                                                     IHC (1:100)
                     anti-Cytokeratin-8                     Studies Hybridoma\     TROMA-I, RRID:[AB_531826](https://scicrunch.org/resolver/AB_531826)           
                                                            Bank                                                                                                 

  Antibody           Rabbit monoclonal\                     Abcam                  Cat. \#:\                                                                     IHC (1:4000)
                     anti-Cytokeratin-\                                            ab181595\                                                                     
                     14                                                            (EPR17350)                                                                    

  Antibody           Rabbit monoclonal\                     Abcam                  Cat. \#:\                                                                     IHC (1:4000)
                     anti-FoxA1                                                    ab173287                                                                      

  Antibody           Rabbit monoclonal\                     Abcam                  Cat. \#:\                                                                     IHC (1:1200)
                     anti-FoxA2                                                    ab108422,\                                                                    
                                                                                   RRID:[AB_11157157](https://scicrunch.org/resolver/AB_11157157)                

  Antibody           Goat polyclonal\                       R and D Systems        Cat. \#:\                                                                     IHC (1:400)
                     anti-Galectin 4                                               AF2128,\                                                                      
                                                                                   RRID:[AB\_](https://scicrunch.org/resolver/AB_2297050)\                       
                                                                                   [2297050](https://scicrunch.org/resolver/AB_2297050)                          

  Antibody           Mouse monoclonal\                      Abnova                 Cat. \#:\                                                                     IHC (1:50)
                     anti-Gastrokine 1                                             H00056287-M01, RRID:[AB_1505437](https://scicrunch.org/resolver/AB_1505437)   

  Antibody           Rabbit monoclonal\                     Abcam                  Cat. \#:\                                                                     IHC (1:5000)
                     anti-GDA                                                      ab210606                                                                      

  Antibody           Rabbit monoclonal\                     Cell Signaling\        Cat. \#:\                                                                     IHC (1:500)
                     anti-HNF4α                             Technology             3113S, RRID:[AB_2295208](https://scicrunch.org/resolver/AB_2295208)           

  Antibody           Rabbit monoclonal\                     Abcam                  Cat. \#:\                                                                     IHC (1:100)
                     anti-Ki67                                                     ab16667, RRID:[AB_302459](https://scicrunch.org/resolver/AB_302459)           

  Antibody           Rabbit polyclonal\                     Abcam                  Cat. \#:\                                                                     IHC (1:800)
                     anti-MCM2                                                     ab31159, RRID:[AB_881276](https://scicrunch.org/resolver/AB_881276)           

  Antibody           Polyclonal goat\                       R and D\               Cat. \#:\                                                                     IHC (1:400)
                     anti-MMP7                              Systems                AF2967, RRID:[AB_664120](https://scicrunch.org/resolver/AB_664120)\           

  Antibody           Mouse monoclonal\                      Abnova                 Cat. \#:\                                                                     IHC (1:100)
                     anti-Muc5AC                                                   MAB13117                                                                      

  Antibody           Rabbit monoclonal\                     Abcam                  Cat. \#:\                                                                     IHC (1:2000)
                     anti-NKX2-1                                                   ab76013, RRID:\                                                               
                                                                                   [AB_1310784](https://scicrunch.org/resolver/AB_1310784)                       

  Antibody           Mouse monoclonal\                      Biocare Medical        Cat. \#: ACI 3066 C                                                           IHC (1:100)
                     anti-p40 (∆Np63)                                                                                                                            

  Antibody           Mouse monoclonal\                      Developmental\         Cat. \#:\                                                                     IHC (1:10)
                     anti-PDX1                              Studies\               F109-D12,\                                                                    
                                                            Hybridoma Bank         RRID:[AB_1](https://scicrunch.org/resolver/AB_1157903)\                       
                                                                                   [157903](https://scicrunch.org/resolver/AB_1157903)                           

  Antibody           Rat monoclonal\                        Abcam                  Cat. \#:\                                                                     IHC (1:400)
                     anti-PIGR                                                     ab170321                                                                      

  Antibody           Rabbit monoclonal\                     Abcam                  Cat. \#:\                                                                     IHC (1:500)
                     anti-PK-LR                                                    ab171744                                                                      

  Antibody           Rabbit polyclonal\                     Millipore              Cat. \#:\                                                                     IHC (1:4000)
                     anti-proSPC                                                   AB3786, RRID:\                                                                
                                                                                   [AB_91588](https://scicrunch.org/resolver/AB_91588)                           

  Antibody           Rabbit polyclonal\                     Rockland               Cat. \#:\                                                                     IHC (1:400)
                     anti-RFP                                                      600-401-379                                                                   

  Antibody           Rabbit monoclonal\                     Cell Signaling\        Cat. \#:\                                                                     IHC (1:250)
                     anti-SOX2                              Technology             3728, RRID:\                                                                  
                                                                                   [AB_2194037](https://scicrunch.org/resolver/AB_2194037)                       

  Antibody           Rabbit monoclonal\                     Abcam                  Cat. \#:\                                                                     IHC (1:1000)
                     anti-VCAM1                                                    ab134047,\                                                                    
                                                                                   RRID:[AB_2721053](https://scicrunch.org/resolver/AB_2721053)                  

  Recombinant\       Ad5-CMVCre                             Gene Transfer\         VVC-U of\                                                                     
  DNA reagent                                               Vector Core,\          Iowa-5-HT                                                                     
                                                            University of\                                                                                       
                                                            Iowa, IA                                                                                             

  Recombinant\       Ad5-CMVFlpo                            Gene Transfer\         VVC-U of\                                                                     
  DNA reagent                                               Vector Core,\          Iowa-530HT                                                                    
                                                            University of\                                                                                       
                                                            Iowa, IA                                                                                             

  Recombinant\       Ad5-SPC-Cre                            Gene Transfer\         VVC-Berns-\                                                                   
  DNA reagent                                               Vector Core,\          1168                                                                          
                                                            University of\                                                                                       
                                                            Iowa, IA                                                                                             

  Recombinant\       Ad5-SPC-FlpO                           Gene Transfer\         VVC-Snyder-\                                                                  
  DNA reagent                                               Vector\                6695                                                                          
                                                            Core, University of\                                                                                 
                                                            Iowa, IA                                                                                             

  Recombinant\       PGK-Cre                                PMID: 19561589                                                                                       
  DNA reagent                                                                                                                                                    

  Recombinant\       VSVg                                   PMID: 19561589                                                                                       
  DNA reagent                                                                                                                                                    

  Recombinant\       Δ8.9                                   PMID: 19561589                                                                                       
  DNA reagent                                                                                                                                                    

  Recombinant\       SPC-FlpO shuttle\                      this paper                                                                                           
  DNA reagent        plasmid                                                                                                                                     

  Chemical\          Tamoxifen                              Sigma-Aldrich          T5648-5G                                                                      
  compound, drug                                                                                                                                                 

  Chemical\          Tamoxifen\                             Envigo                 TD.130858                                                                     500 mg/kg of diet
  compound, drug     supplemented\                                                                                                                               
                     chow                                                                                                                                        

  Chemical\          1X PBS                                 ThermoFisher\          20012050                                                                      
  compound, drug                                            Scientific                                                                                           

  Chemical\          Trizol                                 ThermoFisher\          15596026                                                                      
  compound, drug                                            Scientific                                                                                           

  Commercial\        Bloxall                                Vector\                SP-6000                                                                       
  assay, kit                                                Laboratories                                                                                         

  Commercial\        Horse serum                            Vector\                S-2012                                                                        
  assay, kit                                                Laboratories                                                                                         

   commercial\       Rodent\                                Biocare\               RBM961                                                                        
  assay, kit         Block M                                Medical                                                                                              

  Commercial\        ImmPRESS\                              Vector\                MP-7401                                                                       
  assay, kit         anti-rabbit HRP                        Laboratories                                                                                         

  Commercial\        ImmPRESS\                              Vector\                MP-7444                                                                       
  assay, kit         anti-rat HRP                           Laboratories                                                                                         

  Commercial\        ImmPRESS\                              Vector\                MP-7405                                                                       
  assay, kit         anti-goat HRP                          Laboratories                                                                                         

  Commercial\        Anti-mouse secondary                   Biocare\               MM620                                                                         
  assay, kit                                                Medical                                                                                              

  Commercial\        ImmPACT DAB\                           Vector\                SK-4105                                                                       
  assay, kit         Peroxidase (HRP)\                      Laboratories                                                                                         
                     Substrate                                                                                                                                   

  Commercial\        ImmPACT VIP\                           Vector\                SK-4605                                                                       
  assay, kit         Peroxidase (HRP)\                      Laboratories                                                                                         
                     Substrate                                                                                                                                   

  Commercial\        Hematoxylin                            Fisher\                6765003                                                                       
  assay, kit                                                Scientific                                                                                           

  Commercial\        Collagena\                             ThermoFisher\          17100017                                                                      
  assay, kit         se type I                              Scientific                                                                                           

  Commercial\        Elastase                               Worthington\           LS002280                                                                      
  assay, kit                                                Biochemical\                                                                                         
                                                            Corporation                                                                                          

  Commercial\        Dispase                                Corning                354235                                                                        
  assay, kit                                                                                                                                                     

  Commercial\        Deoxyribonuclease I                    Sigma-Aldrich          DN25                                                                          
  assay, kit                                                                                                                                                     

  Commercial\        Red Blood\                             eBioscience            00-4333-57                                                                    
  assay, kit         Cell Lysis Buffer                                                                                                                           

  Commercial\        PureLink RNA\                          ThermoFisher\          12183018A                                                                     
  assay, kit         Mini kit                               Scientific                                                                                           
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Mice and tumor initiation {#s4-1}
-------------------------

Mice harboring *Kras^LSL-G12D^* ([@bib18]), *Kras^FSF-G12D^* ([@bib58]), *Rosa26^LSL-tdTomato^ ([@bib30])*, *Rosa26^FSF-CreERT2^* (30), *Nkx2-1^F/F^* ([@bib25]), *Foxa1^F/F^* ([@bib10]), *Foxa2^F/F^* ([@bib48]) and CAG-LSL-HA-UPRT ([@bib11]) alleles have been previously described. *Rosa26^LSL-tdTomato^* and CAG-LSL-HA-UPRT mice were obtained from the Jackson Laboratories (Bar Harbor, Maine). All animals were maintained on a mixed C57BL/6J × 129SvJ background. Mice were infected intratracheally with adenovirus (University of Iowa, Gene Transfer Vector Core) or lentivirus as described ([@bib8]). Animal studies were approved by the University of Utah IACUC, and conducted in compliance with the Animal Welfare Act Regulations and other federal statutes relating to animals and experiments involving animals and adhere to the principles set forth in the Guide for the Care and Use of Laboratory Animals, National Research Council (PHS assurance registration number A-3031--01).

Tamoxifen administration {#s4-2}
------------------------

Tamoxifen (Sigma, St. Louis, MO) was dissolved in corn oil to a concentration of 20 mg/ml and administered at a dose of 120 mg/kg per day for 6 doses over 9 days. This was followed by *ad libitum* feeding with tamoxifen-supplemented chow (500 mg/ kg; Envigo, Indianopolis, IN) in place of standard chow for the duration of experiment.

Lentiviral production {#s4-3}
---------------------

Lentivirus was produced by transfection of 293 T cells with TransIT-293 (Mirus Bio, Madison, WI), lentiviral backbone as well as packaging vectors Δ8.9 (gag/pol) and CMV-VSV-G ([@bib8]). Supernatant was collected at 36, 48, 60 and 72 hr after transfection. For in vivo infection, virus was concentrated by ultracentrifugation at 25,000 r.p.m. for 105 min and re-suspended in an appropriate volume of 1X PBS. Cell line identity was authenticated using STR analysis at the University of Utah DNA Sequencing Core. Cells tested negative for mycoplasma.

Cloning {#s4-4}
-------

We first generated a pCDH-SPC-Flpo lentiviral vector by PCR amplifying the murine SPC promoter ([@bib49]) and cloning into SpeI-XbaI sites of pCDH-CMV-Flpo plasmid. The pCDH-mSPC-Flpo vector was then digested with ClaI-PacI and blunt ended with Klenow to clone into EcoRV site of the adenovirus shuttle plasmid G0687 pacAd5mcsSV40pA (University of Iowa, Viral Vector Core Facility). Correct identity and orientation of the construct was confirmed via Sanger sequencing. Further recombination and adenovirus production and purification was carried out by University of Iowa Viral Vector Core (cat.\# VVC-Snyder-6695).

Histology and immunohistochemistry {#s4-5}
----------------------------------

All tissues were fixed in 10% formalin overnight, and lungs were perfused with formalin via the trachea. Tissues were transferred to 70% ethanol, embedded in paraffin, and four-micrometer sections were cut. To detect mucin, sections were stained with 1% Alcian Blue pH 2.5 at the HCI Research Histology Shared Resource. Immunohistochemistry (IHC) was performed manually on Sequenza slide staining racks (ThermoFisher Scientific, Waltham, MA). Sections were treated with Bloxall (Vector labs) followed by Horse serum (Vector Labs, Burlingame, CA) or Rodent Block M (Biocare Medical, Pacheco, CA), primary antibody, and HRP-polymer-conjugated secondary antibody (anti-Rabbit, Goat and Rat from Vector Labs; anti-Mouse from Biocare. The slides were developed with Impact DAB or VIP (Vector) and counterstained with hematoxylin. Slides were stained with antibodies to BrdU (BU1/75, Abcam, Cambridge, MA), Cadherin 13 (EPR9621, Abcam), Cathepsin E (LS-B523, Lifespan Biosciences, Seattle, WA), Caveolin 1 (EPR15554, Abcam), CHIL3/4 (EPR15263, Abcam), Cleaved caspase-3 (5A13, CST, Danvers, MA), Cytokeratin 5 (EP1691Y, Abcam), Cytokeratin 7 (EP17078, Abcam), Cytokeratin-8 (TROMA-I, DSHB, Iowa City, Iowa), Cytokeratin 14 (EPR17350, Abcam), FoxA1 (EPR10881-14, Abcam), FoxA2 (EPR4466, Abcam), Galectin 4 (AF2128, R and D Systems, Minneapolis, MN), Gastrokine 1 (2E5, Abnova, Taipei City, Taiwan), GDA (EPR18751, Abcam), HNF4α (C11F12, CST), KI67 (SP6, Abcam), MCM2 (ab31159, Abcam), MMP7 (AF2967, R and D Systems) Muc5AC (SPM488, Abnova), NKX2-1 (EP1584Y, Abcam), p40(ΔNp63) (BC28, Biocare), PDX1 (F109-D12, DSHB), PIGR (7C1, Abcam), PK-LR (EPR11093P, Abcam), RFP (Rockland Immunochemicals, Limerick, PA), SOX2 (C70B1, CST) and VCAM1 (EPR5047, Abcam). Pictures were taken on a Nikon Eclipse Ni-U microscope with a DS-Ri2 camera and NIS-Elements software. For double immunostaining, slides were blocked sequentially with Bloxall, horse serum and Rodent Block M, then incubated with antibodies of interest from different species (Rabbit and Mouse) simultaneously. Slides were incubated with a mouse secondary followed by DAB (brown). This was followed by incubation with a rabbit secondary antibody and ImPACT VIP (purple, Vector lab). Tumor quantitation was performed on hematoxylin and eosin-stained or IHC-stained slides using NIS-Elements software. All histopathologic analysis was performed by a board-certified anatomic pathologist (E.L.S.).

Fluorescence-activated cell sorting (FACS) {#s4-6}
------------------------------------------

7--20 weeks after tumor initiation with Ad5-SPC-Cre ([@bib49]), tumor-bearing mice were euthanized using carbon dioxide and the rib-cage was dissected to reveal trachea and heart. Cadiac perfusion of the pulmonary vasculature was performed using PBS until the lungs turned pale. The lungs were inflated with an enzymatic digest solution (Collagenase type I (Thermo Fisher Scientific); Elastase (Worthington Biochemical, Lakewood, NJ), Dispase (Corning CB-40235, VWR, Radnor, PA) and Dnase I (DN25, Sigma)) and then minced and digested with the enzyme digest solution at 37 C for 45 min. The digested tissue was then passed through an 18-gauge syringe needle followed by 100, 70 and 40 micron filters to generate a single-cell suspension. The suspension was treated with Red Blood Cell Lysis Buffer (eBioscience, ThermoFisher Scientific,) and then reconstituted in 1X PBS supplemented with 2% fetal bovine serum, 2% BSA and DAPI (Sigma). Cells were sorted using BD FACSAria for tdTomato-positive and DAPI-negative cells into PBS + 10% serum.

Single-cell isolation and RNA sequencing {#s4-7}
----------------------------------------

Sorted tumor cells (200--300 cells/ul) were mixed with C1 Suspension Reagent (Fluidigm, South San Francisco, CA) and loaded on a 5--10 μm C1 Single-cell Auto Prep IFC for mRNA Seq (Fluidigm cat\# 100--5760). Captured cells were visualized and scored by microscopy. Amplified cDNA products derived from captured cells were harvested and concentrations were measured using the Qubit dsDNA HS Assay Kit. Amplified products were normalized to a concentration of 0.2 ng/ul and sequencing libraries were prepared using the Nextera XT DNA Library Preparation Kit (cat\# FC131-1096, Illumina, San Diego, CA) and dual indexed adapters (FC-131--2001, FC-131--2002) according to the modified protocol described by Fluidigm. Purified libraries were qualified on an Agilent Technologies 2200 TapeStation using a D1000 ScreenTape assay (cat\# 5067--5582 and 5067--5583). The molarity of adapter-modified molecules was defined by quantitative PCR using the Kapa Biosystems (Wilmington, MA) Kapa Library Quant Kit (cat\# KK4824). Individual libraries were normalized to 10 nM and equal volumes were pooled in preparation for Illumina sequence analysis.

Sequencing libraries (25 pM) were chemically denatured and applied to an Illumina HiSeq v4 single read flow cell using an Illumina cBot. Hybridized molecules were clonally amplified and annealed to sequencing primers with reagents from an Illumina HiSeq SR Cluster Kit v4-cBot (GD-401--4001). Following transfer of the flowcell to an Illumina HiSeq 2500 instrument (HCSv2.2.38 and RTA v1.18.61), a 50-cycle single-read sequence run was performed using HiSeq SBS Kit v4 sequencing reagents (FC-401--4002).

Processing and analysis of single-cell RNA-seq data {#s4-8}
---------------------------------------------------

### Transcript expression estimation {#s4-8-1}

The genome index was created with STAR (v2.4.2a) ([@bib7]) using the mm10 genome sequence and Ensembl (build 85) gene definitions. Reads were aligned to the index using the following parameters: outFilterType BySJout, outFilterMultimapNmax 20, outFilterMismatchNmax 999, outFilterMismatchNoverReadLmax 0.04, alignIntronMin 20, alignIntronMax 1000000, alignMatesGapMax 1000000, alignSJoverhangMin 8, alignSJDBoverhangMin 1, sjdbScore 1, outSAMtype BAM SortedByCoordinate, quantMode TranscriptomeSAM.

The RSEM (v1.2.19) ([@bib27]) reference was created using the rsem-prepare-reference command. Gene estimates were generated by running rsem-calculate-expression on the STAR alignments.

### Clustering {#s4-8-2}

The gene count estimates from RSEM were loaded into a scater (v1.2.0) ([@bib33]) SCESet object. Genes with log2(CPM) \>2 in at least 10 cells were retained in the analysis. Cells with greater than 20% mitochondrial reads, less than 500 thousand alignments, less than 500 measurable genes or less than 20% mRNA bases were removed from the analysis. SC3 (v1.3.18) ([@bib22]) was run on the filtered SCESet object using k = 3 and gene filtering turned off. The resulting cell cluster assignments and marker genes were used in the remaining analyses. The scater 'plotTSNE' function was used to generate t-distributed stochastic neighbor embedding (t-SNE) plot.

AT2 gene count estimates (E18.5 cells, Treutlein et al.) were added to the passing cells from the previous analysis. SC3 and scater were run using the parameters listed above.

### Differential expression {#s4-8-3}

Differential expression between the clusters was determined using the Bioconductor package SCDE (v1.99.1) ([@bib20]). RSEM gene count estimates from cells passing filtering were used in this analysis. Genes were retained if there were 10 or more counts in at least 10 cells. Error models were fit using the 'scde.error.models' function, expression magnitude priors for the genes were generated using the 'scde.expression.prior' function and differential expression was determined with the 'scde.expression.difference' function set to 100 randomizations.

### Correlation with bulk RNA-Seq data {#s4-8-4}

The differential expression results from the bulk cell and single cell analyses were intersected. Genes with an average count less than 1000 in the bulk cell samples were removed. The log2 fold change values from both analyses were plotted using ggplot2 (v2.2.1) ([@bib12]). The Pearson correlation coefficient was calculated using the base R (v3.3.2) function cor.test.

### IMA signature {#s4-8-5}

Transcripts per Million (TPM) estimates from RSEM were extracted for cells passing filtering and restricted to genes found in the human IMA signature ([@bib14]). The FactoMineR (v1.39) ([@bib26]) function 'PCA' was run on the log-transformed TPM values and the first two components were plotted using ggplot.

### Normal tissue classification {#s4-8-6}

TPM values were generated for each cluster by summing gene counts across the members of the cluster and dividing by the RSEM estimated gene length in kilobases to get the counts per base rate of each gene. These rates are divided by the sum of all rates and scaled by a million to get TPM. The TPM values for each cluster were then intersected with bulk cell TPM and normal tissue TPM downloaded from Encode ([Supplementary file 5](#supp5){ref-type="supplementary-material"}). Gene were restricted to those classified as 'protein coding' by Ensembl and had at least 10 counts in 10 or more cells.

High-expressing genes for each normal tissue were selected by first calculating the average tissue log2 CPM for each gene, which were then mean-centered across all tissues. The tissue with the highest expression was assigned its own mean-centered expression value. Once all genes were processed, the assigned genes in each tissue were ranked by expression and the top 70 were reported.

The Rtnse (v0.13) ([@bib23]) function 'Rtsne' was used to generate a tSNE plot on the log2 TPM values of the tissue enriched genes. The perplexity was set to 13 and the initial dimensions was set to 5.

The FactoMineR function 'PCA' was run on the log2 TPM values with scaling turned off and five dimensions. The FactorMineR function 'HCPC' was then used perform a hierarchical clustering on principle component (HCPC) analysis on the PCA result.

Cosine similarity was calculated using the lsa (v0.73.1) ([@bib56]) function 'cosine'. Every combination of cluster and normal tissue log2 TPM values were compared.

Bulk RNA isolation and total RNA-Seq {#s4-9}
------------------------------------

RNA was isolated by trizol-chloroform extraction followed by column-based purification. Sorted cells were lysed in 1 ml Trizol (ThermoFisher Scientific), followed by phenol-chloroform extraction. The aqueous phase was brought to a final concentration of 50% ethanol, and RNA was purified using the PureLink RNA Mini kit according to the manufacturer's instructions (ThermoFisher Scientific). Library preparation was performed using the TruSeq Stranded RNA kit with Ribo-Zero Gold (Illumina). Libraries were sequenced on an Illumina HiSeq 2500 (50 cycle single-read sequencing).

Processing and analysis of total RNA-seq data {#s4-10}
---------------------------------------------

Mouse FASTA and GTF files were downloaded from Ensembl release 82 and a reference database was created using RSEM version 1.2.12 ([@bib27]). RSEM and the Bowtie 1.0.1 aligner were used to map reads and estimate transcripts and gene counts using rsem-calculate-expression with the forward-prob 0 option for reversely stranded Illumina reads. The expected gene counts were filtered to remove 12371 features with zero counts and 10100 features with fewer than 10 reads in any sample. Differentially expressed genes were identified using a 5% false discovery rate with DESeq2 version 1.16.0 (59).

Histopathologic evaluation of primary human tumors {#s4-11}
--------------------------------------------------

Formalin fixed, paraffin-embedded (FFPE) tumors were obtained in accordance with protocols approved by the Institutional Review Boards of the University of Utah and Intermountain Healthcare. Additional lung adenocarcinomas were evaluated on commercially available tissue microarrays (US BioMax, Rockville, MD).

Comparison of *FOXA1* and *FOXA2* levels in *KRAS*-mutant human lung adenocarcinomas {#s4-12}
------------------------------------------------------------------------------------

The patient IDs and cluster names from 68 KRAS-mutants listed in supplementary figure 2A in [@bib45] were saved to a sample table with 23 KL, 30 KP and 15 KC samples corresponding to genetic alterations in STK11/LKB1 (KL), TP53 (KP), and CDKN2A/B inactivation coupled with low expression of NKX2-1 (KC). The patient IDs were matched to a count matrix from the TCGA Lung Adenocarcinoma project (LUAD) using the TCGAbiolinks package and HTSeq counts in the GDC harmonized dataset ([@bib5]). Eleven patients with a matched normal sample were also included as a fourth group for comparison. The count matrix was filtered to remove 5789 features with zero counts and 19,546 features with fewer than 10 reads in any sample. The sample table and filtered count matrix were loaded into DESeq2 version 1.16.0 (59) to estimate normalized counts and identify differentially expressed genes using a 5% false discovery rate.

Statistics {#s4-13}
----------

*p*-Values were calculated using the unpaired two-tailed Mann-Whitney (non-parametric) U test, Chi-squared test or Fisher's Exact Test. RNA-Seq statistics are described above.
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Data availability {#s7}
-----------------

All data generated or analysed during this study are included in the manuscript and supporting files. Sequencing data will be deposited in GEO under accession codes GSE115901.

The following dataset was generated:
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Reviewing Editor

Memorial Sloan Kettering Cancer Center

United States

In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your manuscript entitled \"FoxA1 and FoxA2 are required for gastric differentiation in NKX2-1-negative lung adenocarcinoma\" for peer review at *eLife*. Your article has been evaluated by three peer reviewers, and the evaluation was overseen by a Reviewing Editor and a Senior Editor.

As you will see below, each of the reviewers was generally enthusiastic about the fundamental observations you made about FoxA genes in lung cancer. However, overall, there was significant concern that you have not really been able to discern two potential explanations for your findings: 1) a single cell of origin accompanied by an epigenetic shift, versus 2) two different cells of origin. This is considered a major impediment to publication since these would suggest significantly different mechanisms for your observations.

We recognize that clarifying this experimentally may be very challenging, especially within the two month time frame for eLife revisions. Based on this, what I would request is that you look over the critiques below and provide a detailed plan for what you think you could achieve to address them within a two month window. We will then look over your proposed plan of action and editorially decide if we want to proceed. If we decide to proceed, we would then give you two months to accomplish what you stated and have the revised manuscript re-reviewed by the original reviewers.

*Reviewer \#1:*

In this study, Camolotto et al. have investigated lung adenocarcinoma progression with a specific focus on the mechanisms of how cellular identity evolves in Nkx2.1 mutant invasive mucinous adenocarcinomas. They conclude that both *Foxa1* and *Foxa2* are required for the maintenance of the adenocarcinoma phenotype. Interestingly, the timing of *Foxa1/2* inactivation determined the outcome of the eventual tumor phenotype.

The study is carefully executed and employs state-of-the-art approaches such a series of elegant genetically engineered mouse models as well as single-cell mRNA sequencing. The manuscript is well-written and the data are clearly presented. The manuscript is important, providing mechanistic insight into how cellular identity is transcriptionally regulated. The manuscript motivates further studies into identifying how epigenetic and genetic states dictate the outcome of lineage-determining transcription factors.

Major concern

The genetic evidence for the role of *Foxa1/2* in preserving lung adenocarcinoma identity in the mouse model is clear. However, the manuscript would greatly benefit from a comparison with human adenosquamous lung cancers. In human IMA, Nkx2.1 is often inactivated through point mutations that do not necessarily inactivate all functions of the protein (DNA binding, *Foxa1/2* binding, association with upstream regulators). In contrast, the mouse model produces a full deletion of both copies of Nkx2-1, leading to complete absence of the protein. Thus, the mechanism by which adenosquamous tumors arise may be different. At least computational analyses or additional discussion should be provided.

Overall, this is a high quality study and appropriate for the readership of *eLife*.

*Reviewer \#2:*

In this manuscript Camolotto et al. provide evidence for *Foxa1* and *Foxa2* activating the expression of gastrointestinal genes in *Kras^LSL-G12D/+^*;*Nkx2-1^F/F^* driven ADC lesions in mice carrying either *Foxa1/2* deletions. It has been previously described that normal and neoplastic epithelial cells adopt a gastric differentiation state after *Nkx2-1* deletion and that the re-localization of the transcription factors *Foxa1* and *Foxa2* from pulmonary to gastrointestinal genes is the mechanism responsible for this change in differentiation (Snyder et al., 2013).

The authors show that *Foxa1/2* deletions correlates, in some cases, with squamous differentiation of tumor lesions. Since lung SCC is found adjacent to lung ADC (Adenosquamous lesions) in mice genetically proficient for either *Foxa1* or *Foxa2*, but actually negative for the expression of both, they suggest that only when the expression of one of the two genes is stochastically lost, mice develop SCC. In contrast, when both *Foxa1* and *Foxa2* are genetically deleted from the beginning, mice develop ADC expressing markers of the squamo-columnar junction of the gastrointestinal tract. They suggest that this difference is attributable to a different context in which the lineage specifier is lost.

In general, the idea that the effects of lineage specifier inactivation in cancer can be highly context-dependent is intriguing. However, the experiments as described lack important controls and quantifications to firmly conclude this.

Point by point discussion:

In invasive mucinous ADC (IMA) (Guo et al., 2017) *Foxa2* is not found commonly upregulated. However, *Foxa3* is, and it produces mucinous ADC in transgenic mouse models. Actually, *Foxa3* and 1 are the commonly upregulated genes in human and mouse IMA (Guo M). Does the expression of *Foxa3* change in mice upon *Foxa1/2* deletion? Can the authors exclude that HNF4α expression in *Foxa1/2^F/F^*mice is activated by *Foxa3*? To confirm that *Foxa1/2* are indeed re-localized upon *Nkx2-1* deletion, include *Kras^LSL-G12D/+^* mice proficient for *Nkx2-1* in the IHC panel of Figure 1. Add *Foxa3* staining.

The authors report a \"variable but substantial\" quantity of \"incomplete recombinants\" when they refer to mice carrying the double conditional deletion of *Foxa1* and *Foxa2*. This needs substantiation at the different time points. If incomplete recombination is responsible for the tumor outgrowth one would expect regions that are highly positive for either FoxA1 or A2 (as seen in the *Foxa1* or *Foxa2* single knockouts). However, the staining is rather dispersed as if deletion of non-recombined alleles continues. How do the authors reconcile this with the prolific outgrowth of partial recombinants? If recombination does indeed proceed (through lentiviral Cre expression) this then should promote squamous differentiation according to the model the authors propose but this does not occur.

Can the authors formally exclude that instead of incomplete recombination, the result is due to the fact that *Foxa1* and *Foxa2* deletion is just not sufficient to suppress the gastric differentiation? What about FoxA3?

The authors use subsequently 2 different models to support the context-dependence of LCC development: i) *Kras^FSF-G12D/+^*;*Rosa^FSF-CreERT2^; Nkx2-1^F/F^*; *Foxa1F/F; FoxaF/F* mice in which mutant *Kras* is first activated via Ad5CMV-FlpO, and one week later, tamoxifen is administered to activate *Foxa1/2* deletions. The sequential introduction of these lesions results in LSCC which is already detectable at 5 weeks. ii) *KrasG12D /+; Nkx2-1F/F*; *Foxa1F/F; FoxaF/F* mice infected with Ad5-CMV-Cre; at 5 weeks no LSCC is found. They conclude that in the context in which mutant *Kras* is already activated, *Foxa1/2* deletion gives rise to SCC; when mutations occur at the same time, mice develop ADC. This possible, but this requires better control of the experiment. They need to assess potential effects of tamoxifen treatment (e.g. by giving Tamoxifen also in the model in \"ii\". They should also analyze mice after a longer period.

Can the authors exclude that markers for the squamo-columnar junction cells of the gastrointestinal tract, are shared with precursors of lung SCC? It would help to include other markers of SCC, such as K5, K14, SOX2, which are also robust markers and are already expressed in intermediate lesions committed to squamous differentiation.

*Reviewer \#3:*

Camolotta and colleagues examine the consequences of deleting *Nkx2-1, Foxa1* and *Foxa2* in the *Kras^G12D^* lung adenocarcinoma model. Previously, they had shown that deletion of *Nkx2-1* in *Kras^G12D^* -driven lung adenocarcinoma results in mucinous conversion with corresponding molecular switch from lung to gastric epithelial identity. Here, they report that deletion of *Nkx2-1, Foxa1* and *Foxa2* following *Kras^G12D^* initiation results in squamous transdifferentiation with lack of gastric marker expression. However, when the factors are deleted concomitant with *Kras^G12D^* induction, a different tumor phenotype results and cells have molecular features of the squamocolumnar junction (SCJ) of the GI tract. The authors speculate that the differential effect from sequential manipulation results from epigenetic changes induced by Kras activity.

The main conclusion of the work and title of the manuscript, that it is *Foxa1* and *Foxa2* that mediate the gastric differentiation in *Nkx2-1* negative lung adenocarcinoma, is entirely unsurprising. *Foxa1* and *Foxa2* are already known to directly regulate expression of gastric target genes, so clearly their deletion in *Nkx2-1* deficient tumor cells should compromise expression of gastric markers. This finding by itself does not really represent a significant advance in the field.

The different phenotypes resulting from concurrent deletion and activation of *Kras^G12D^* versus deletion seven days after induction of *Kras* is very interesting, but no evidence that this is due to epigenetic changes induced by *Kras* is provided. It seems at least equally plausible that the distinct tumor histology represents transformation of a different (non-AT2) cell type. This alternate model would also explain why there was a reduction in tumor number, since if only the molecular identity and proliferation of recombined AT2 cells were influenced, one might expect the same number of tumors but of smaller size. There were also fewer tumors when only *Foxa1* was deleted, which they did not attempt to explain. Unfortunately, without inducing *Kras^G12D^* in a cell type-specific manner, it is impossible to deconvolute the cell of origin retrospectively, particularly when the tumor lacks expression of lung cell type markers. So, I don\'t feel there is really any reasonably supported explanation for this important finding, and whether it results from an epigenetic effect versus a different cell of origin would drastically alter the model.

Regarding the possibility that the molecular phenotype of these small tumors is of SCJ cells, it is unclear why this would be the case, since SCJ cells apparently express *Foxa1*. Wouldn\'t deletion of *Nkx2-1* and *Foxa2* thus be more likely to induce a SCJ identity than deletion of all three factors? So, without further exploration this interpretation seems provisional.
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Author response

\[Editors\' note: the authors' plan for revisions was approved and the authors made a formal revised submission.\]

> As you will see below, each of the reviewers was generally enthusiastic about the fundamental observations you made about FoxA genes in lung cancer. However, overall, there was significant concern that you have not really been able to discern two potential explanations for your findings: 1) a single cell of origin accompanied by an epigenetic shift, versus 2) two different cells of origin. This is considered a major impediment to publication since these would suggest significantly different mechanisms for your observations.

We are grateful to the reviewers for their thoughtful and constructive comments, and appreciate their overall enthusiasm for our work. We are excited to report that we have been able to develop a novel adenovirus that allows us to address the major concern about cell of origin enumerated in the summary letter. In brief, we now show that SPC-positive lung epithelial cells can give rise to squamous cell carcinoma upon loss of NKX2-1, FoxA1 and FoxA2. Please see below for detailed response to each reviewer.

> Reviewer \#1:
>
> \[...\] The genetic evidence for the role of Foxa1/2 in preserving lung adenocarcinoma identity in the mouse model is clear. However, the manuscript would greatly benefit from a comparison with human adenosquamous lung cancers. In human IMA, Nkx2.1 is often inactivated through point mutations that do not necessarily inactivate all functions of the protein (DNA binding, Foxa1/2 binding, association with upstream regulators). In contrast, the mouse model produces a full deletion of both copies of Nkx2-1, leading to complete absence of the protein. Thus, the mechanism by which adenosquamous tumors arise may be different. At least computational analyses or additional discussion should be provided.

We agree that our murine studies raise the question of whether loss of FoxA1/2 expression is also observed in human AdSCC. To address this question, we have obtained tissue sections from 12 primary human AdSCC cases in which levels of both FoxA1 and FoxA2 could be evaluated by IHC in both the adenocarcinoma (ACA) and squamous (SCC) components. In six cases, FoxA1 and FoxA2 were both downregulated in the SCC component compared with the ACA component. In five cases, only FoxA2 was downregulated in the SCC (FoxA1 was expressed in both components) and in one case, FoxA1 was downregulated in SCC (FoxA2 was expressed in both components). We have added a graph and representative images (Figure 4D-E) reflecting these new data. These data show that FoxA1/2 downregulation is associated with squamous differentiation in human AdSCC. Human cancers are more heterogeneous than any given mouse model, so it is not surprising that we observe more than one distinct pattern of changes in FoxA1/2 levels in these cases. Nevertheless, the fact that all cases exhibited lower levels of FoxA1 and/or FoxA2 in the SCC component suggests that our results are highly relevant to the human disease, and that loss of these transcription factors may also be causative for adenosquamous transdifferentiation in human lung cancer. Although we don't have access to genetic analysis of these samples, we predict that mutational spectrum and/or cell of origin may dictate whether loss of one or both FoxA transcription factors is sufficient for squamous transdifferentiation in this disease.

> Overall, this is a high quality study and appropriate for the readership of eLife.
>
> Reviewer \#2:
>
> \[...\] In general, the idea that the effects of lineage specifier inactivation in cancer can be highly context-dependent is intriguing. However, the experiments as described lack important controls and quantifications to firmly conclude this.
>
> Point by point discussion:

*In invasive mucinous ADC (IMA) (Guo et al., 2017) Foxa2 is not found commonly upregulated. However, Foxa3 is, and it produces mucinous ADC in transgenic mouse models. Actually, Foxa3 and 1 are the commonly upregulated genes in human and mouse IMA (Guo M). Does the expression of Foxa3 change in mice upon Foxa1/2 deletion? Can the authors exclude that HNF4α expression in Foxa1/2^F/F^mice is activated by Foxa3? To confirm that Foxa1/2 are indeed re-localized upon Nkx2-1 deletion, include KrasLSL-G12D/+ mice proficient for Nkx2-1 in the IHC panel of Figure 1. Add Foxa3 staining.*

Although *Foxa2* is not commonly upregulated at the mRNA level in human IMA, it is readily detectable at the protein level in this disease (Figure 1---figure supplement 1A). Our single cell RNA-Seq data (Supplementary file 3) shows that *Foxa3* is more highly expressed in cluster C2 (KN) than C3 (KNF1F2) or C1 (K), demonstrating that FoxA1/2 drive *Foxa3* expression in NKX2-1-negative tumors. (*Foxa3* is also higher in KN vs. K tumors in our total RNA-Seq analysis, Supplementary file 4). Unfortunately, we were not able to identify commercially available IHC-quality antibody to characterize FoxA3 at the protein level. Review of the literature indicates that the polyclonal antibody sc-5361 has been used by other authors in IHC. However, this antibody has been discontinued by the manufacturer (Santa Cruz). Nevertheless, it is clear from our RNA-Seq data that FoxA1/2 are required for expression of both HNF4α and FoxA3. The experiments in this manuscript are not designed to test the regulatory interaction between HNF4α and FoxA3. There are several lineage specifiers regulated by FoxA1/2 in NKX2-1-negative lung adenocarcinoma (including PDX1, HNF4γ and HNF1α), and in future work it would be interesting to define their hierarchical regulatory interactions. We do not believe it is necessary to include IHC on NKX2-1 positive tumors because they have been shown to lack gastric markers in Snyder et al., 2013 and Maeda et al. JCI 2012. This is further demonstrated by the RNA-seq data presented in this manuscript (Supplementary files 3-4). We also extensively characterized FoxA1/2 re-localization by ChIP-seq in Snyder et al., 2013.

> The authors report a \"variable but substantial\" quantity of \"incomplete recombinants\" when they refer to mice carrying the double conditional deletion of Foxa1 and Foxa2. This needs substantiation at the different time points. If incomplete recombination is responsible for the tumor outgrowth one would expect regions that are highly positive for either FoxA1 or A2 (as seen in the Foxa1 or Foxa2 single knockouts). However, the staining is rather dispersed as if deletion of non-recombined alleles continues. How do the authors reconcile this with the prolific outgrowth of partial recombinants? If recombination does indeed proceed (through lentiviral Cre expression) this then should promote squamous differentiation according to the model the authors propose but this does not occur.
>
> Can the authors formally exclude that instead of incomplete recombination, the result is due to the fact that Foxa1 and Foxa2 deletion is just not sufficient to suppress the gastric differentiation? What about FoxA3?

In the original manuscript, we carefully quantitated the relative proportion of incomplete recombinants at multiple timepoints in Figure 2---figure supplement 1A. In this graph, we show that the proportion of HNF4α-positive incomplete recombinants increases over time, consistent with the growth advantage we would expect from the data presented in Figure 2. These HNF4α-positive incomplete recombinants always retain either FoxA1 and/or FoxA2 expression. Thus, we infer that expression of Cre has been lost in these lesions. This is an expected result since lentiviral integration into the genome is random and genes delivered by the lentivirus can be readily downregulated. We have added a photomicrograph of an incomplete recombinant to further illustrate this point (Figure 2---figure supplement 1B).

In response to the comment: "the staining is rather dispersed as if deletion of non-recombined alleles continues".If thisrefers to Figure 1, we want to clarify that the photomicrographs in this figure all show complete recombinants. FoxA1/2-positive cells in pictures from *Foxa1/2* conditional mice are normal type 2 pneumocytes that are dispersed throughout the alveoli and sometimes found intermingled with neoplastic lesions of all genotypes. To be clear, complete recombinants in *Foxa1/2* conditional mice exhibit no staining for FoxA1 or FoxA2 protein by IHC, and are morphologically quite distinct from incomplete mucinous recombinants.

Overall, our data are conclusive that *Foxa1/2* deletion is sufficient to suppress gastric differentiation, including *Foxa3* expression.

> The authors use subsequently 2 different models to support the context-dependence of LCC development: i) KrasFSF-G12D/+; RosaFSF-CreERT2; Nkx2-1F/F; Foxa1F/F; FoxaF/F mice in which mutant Kras is first activated via Ad5CMV-FlpO, and one week later, tamoxifen is administered to activate Foxa1/2 deletions. The sequential introduction of these lesions results in LSCC which is already detectable at 5 weeks. Ii) KrasG12D /+; Nkx2-1F/F; Foxa1F/F; FoxaF/F mice infected with Ad5-CMV-Cre; at 5 weeks no LSCC is found. They conclude that in the context in which mutant Kras is already activated, Foxa1/2 deletion gives rise to SCC; when mutations occur at the same time, mice develop ADC. This possible, but this requires better control of the experiment. They need to assess potential effects of tamoxifen treatment (e.g. by giving Tamoxifen also in the model in \"ii\".

The mice that developed AdSCC in Figure 4 did not receive tamoxifen treatment, supporting the notion that tamoxifen is not likely to mediate or be required for squamous transdifferentiation. In addition, the experiments shown in Figure 5 include two controls of distinct genotypes (*Foxa1/2*^+/+^, *Foxa2*^F/F^ and *Foxa1/2*^F/F^). All three genotypes received tamoxifen, but only the latter group developed SCC. To further control for the effects of tamoxifen, we have included new data (Figure 6) showing that tamoxifen treatment of *Kras^LSL-G12D/+^; Nkx2-1^F/F^; Foxa1^F/F^; Foxa2^F/F^*mice infected with Ad5-SPC-Cre does not lead to SCC formation, whereas tamoxifen treatment of *Kras^FSF-G12D/+^;Rosa^FSF-CreERT2^; Nkx2-1^F/F^; Foxa1^F/F^; Foxa2^F/F^*mice infected with Ad5-SPC-FlpO does lead to SCC formation.

> They should also analyze mice after a longer period.

We are currently aging a cohort of *Kras^FSF-G12D/+^; Rosa^FSF-CreERT2^; Nkx2-1^F/F^; Foxa1^F/F^; Foxa2^F/F^*mice (and of *Kras^FSF-G12D/+^; Rosa^FSF-CreERT2^; Nkx2-1^F/F^* controls) infected with low dose Ad5CMV-FlpO followed by tamoxifen 1 week later. This experiment is not complete, so we would prefer not to include it in the main manuscript. However, we can report that all four of the *Foxa1^F/F^; Foxa2^F/F^*mice analyzed by histopathology so far harbor multiple SCCs (some macroscopic in size) as well as microscopic SCJ-like lesions. In contrast, none of the five controls analyzed so far harbor SCCs, but rather contain mucinous lesions as expected from *Nkx2-1* deletion.

Although this experiment is informative and expands on the shorter term studies included in the manuscript, it does not alter any of our fundamental conclusions.

> Can the authors exclude that markers for the squamo-columnar junction cells of the gastrointestinal tract, are shared with precursors of lung SCC?

As shown in Figure 3, markers of the SCJ are not expressed in invasive mucinous adenocarcinoma, which appears to be the precursor of the SCC component of the AdSCC lesions we describe in Figure 4. We have not identified a specific precursor lesion of the squamous lesions shown in Figures 5-6, so we can't address that question for these lesions. It is formally possible that the squamous lesions shown in Figure 5-6 arise from a transient precursor expressing SCJ markers. Alternatively, these squamous lesions may arise directly from KRAS^G12D^-expressing cells upon deletion of *Nkx2-1, Foxa1* and *Foxa2*.

> It would help to include other markers of SCC, such as K5, K14, SOX2, which are also robust markers and are already expressed in intermediate lesions committed to squamous differentiation.

IHC for SOX2 and K14 is shown in Figure 4---figure supplement 1C. Interestingly, SOX2 is not expressed in either the adenocarcinoma or SCC component of the tumors. K14 is upregulated in SCC. We have provided additional IHC for K5, which is positive in SCC as expected (Figure 3---figure supplement 1, Figure 4---figure supplement 1, and Figure 6).

> Reviewer \#3 (General assessment and major comments (Required)): \[\...\] The different phenotypes resulting from concurrent deletion and activation of KrasG12D versus deletion seven days after induction of Kras is very interesting, but no evidence that this is due to epigenetic changes induced by Kras is provided. It seems at least equally plausible that the distinct tumor histology represents transformation of a different (non-AT2) cell type. This alternate model would also explain why there was a reduction in tumor number, since if only the molecular identity and proliferation of recombined AT2 cells were influenced, one might expect the same number of tumors but of smaller size. There were also fewer tumors when only Foxa1 was deleted, which they did not attempt to explain. Unfortunately, without inducing KrasG12D in a cell type-specific manner, it is impossible to deconvolute the cell of origin retrospectively, particularly when the tumor lacks expression of lung cell type markers. So, I don\'t feel there is really any reasonably supported explanation for this important finding, and whether it results from an epigenetic effect versus a different cell of origin would drastically alter the model.

To address the cell of origin question, we have generated an adenovirus expressing FlpO from the SPC promoter (Ad-SPC-FlpO). The SPC promoter has previously been used by Anton Berns and others to drive Cre expression specifically in SPC-positive type 2 pneumocytes of the lung (Sutherland et al., 2011). We used this virus to specifically target SPC-positive cells in *Kras^FSF-G12D/+^; Rosa^FSF-CreERT2^; Nkx2-1^F/F^; Foxa1^F/F^; Foxa2^F/F^*mice. As shown in the new Figure 6, infection with Ad-SPC-FlpO followed by tamoxifen 1 week later leads to the development of both keratinizing squamous cell carcinoma lesions and SCJ-like lesions at the 5 week timepoint (similar to the phenotypes we observed with the CMV-FlpO adenovirus, Figure 5). Thus, SCC can arise from SPC-positive cells. The fact that SPC-positive cells can frequently give rise to SCC in this experiment is particularly surprising given recent work (Nagaraj et al., 2017) showing that squamous lesions in *Kras; Lkb1* conditional mice arise almost exclusively from CC10-positive cells rather than SPC-positive cells. These data suggest an unexpected degree of lineage plasticity within the SPC-positive population.

Although these data show that loss of three lineage specifiers (NKX2-1, FoxA1 and FoxA2) is sufficient for SCC formation in SPC-positive cells, they also raise the question of why SPC-positive cells can give rise to two distinct phenotypes upon the same genetic manipulation (CK5-positive SCC vs. CK7-positive SCJ-like lesions). In the Discussion, we point to various potential sources of this heterogeneity, including cell cycle status at the time of lineage specifier deletion, heterogeneity within the SPC-positive population, or even purely stochastic elements. Investigating these alternatives will likely form the basis of a future manuscript.

> Regarding the possibility that the molecular phenotype of these small tumors is of SCJ cells, it is unclear why this would be the case, since SCJ cells apparently express Foxa1. Wouldn\'t deletion of Nkx2-1 and Foxa2 thus be more likely to induce a SCJ identity than deletion of all three factors? So, without further exploration this interpretation seems provisional.

We agree that cancer cells are fundamentally sui generis and have tried not to overinterpret the data or argue that they are exactly the same as any normal cell type. Nevertheless, it is striking that many SCJ markers are upregulated in cancer cells that concomitantly lose NKX2-1, FoxA1 and FoxA2. Moreover, these tumor cells still cluster with the normal upper GI tract in our bioinformatic analysis. Taken together, these data suggest that they are more like SCJ cells than any other discrete cell type we have been able to identify. We respectfully disagree with the argument that deletion of *Nkx2-1* and *Foxa2* would be more likely to induce an SCJ-like identity. Through careful titration of FoxA1 IHC, we have found that FoxA1 levels at the SCJ are extremely low (much lower than FoxA1 levels in *Nkx2-1/Foxa2* deleted tumors) (Figure 3---figure supplement 1F vs. Figure 1). We have added arrows to this figure to make this point clear. Thus, we would argue that overall FoxA1/2 activity at the SCJ is likely to be much lower than in *Nkx2-1/Foxa2* deleted tumors. Unfortunately, there is no publicly available gene expression data for the recently described KRT7-positive SCJ cells identified by Jiang et al. (Jiang et al., 2017), and we do not have the tools to isolate these cells ourselves.

> "There were also fewer tumors when only Foxa1 was deleted, which they did not attempt to explain."

Although *Foxa1* deletion had a mild effect on tumor burden, it had no effect on proliferation rate or overall survival. Indeed, the most striking effect of *Foxa1* deletion was enhanced mucin secretion at late timepoints (Figure 2---figure supplement 1I). Although we suspect that FoxA1 and FoxA2 have some non-redundant functions in NKX2-1-negative tumors, we found that deleting both led to much more significant phenotypes, and thus we prioritized the analysis of complete FoxA1/2 loss as being the most impactful area of investigation.

[^1]: These authors contributed equally to this work.
